

October 15, 2007

CURRICULUM VITAE

NAME: GARY HERBERT LYMAN

CAMPUS ADDRESS: Duke University Medical Center
Box 3645
Hock Plaza, Suite 602, Rm 6038
2424 Erwin Road
Durham; NC 27705

MAILING ADDRESS: Duke University Medical Center
DUMC 3645
Durham, NC 27710

BUSINESS PHONE: (919) 681-1604

BUSINESS FAX: (919) 681-7488

E-MAIL: Gary.Lyman@Duke.edu



UNDERGRADUATE EDUCATION:



State University of New York at Buffalo
Degree: Bachelor of Arts (B.A.) 1964-1968
Majors-Psychology; Physics

GRADUATE EDUCATION:

State University of New York at Buffalo, School of Medicine,
Degree: Doctor of Medicine (M.D.) 1968-1972

State University of New York at Buffalo
Department of Biophysics 1971-1972

State University of New York at Buffalo
Department of Experimental Pathology 1974-1977

Harvard University School of Public Health
Degree: Master of Public Health (M.P.H.)
Biostatistics 1981-1982

University of South Florida College of Natural Sciences
Department of Mathematics 1983-1987

POSTGRADUATE EDUCATION:

University of North Carolina, Chapel Hill, North Carolina
Straight Medical Internship 1972-1973
Junior Assistant Medical Residency 1973-1974

Roswell Park Memorial Institute, Buffalo, New York
Clinical Medical Oncology Fellowship 1974-1976
Junior Cancer Research Internist 1976-1977

Dana Farber Cancer Institute, Boston, Massachusetts
Research Fellow 1981-1982

EDUCATIONAL FELLOWSHIPS:

Roswell Park Memorial Institute American Cancer Society Clinical Fellow 1974-1976

Roswell Park Memorial Institute American Cancer Society Junior Faculty Clinical Fellow 1976-1977

Roswell Park Memorial Institute Leukemia Society of America Special Fellow 1976-1977

Harvard University NIH Postdoctoral Fellow 1981-1982

BOARD CERTIFICATION:

Diplomate, National Board of Medical Examiners 07-02-73

Diplomate, American Board of Internal Medicine 06-18-75

Diplomate, Subspecialty of Medical Oncology, ABIM	10-18-77
Diplomate, Subspecialty of Hematology, ABIM	10-01-78
Advanced Achievement, American Board of Internal Medicine	08-14-87

<u>LICENSURE:</u>	North Carolina	_____	08-27-07
	New York	_____	11-07-74
	Florida	_____	07-19-77
	Massachusetts	_____	07-22-81

PROFESSIONAL HONORS:

James A. Gibson Honor Society (State University of New York)	1970
Bernhardt and Sophie B. Gottlieb Award (State University of New York)	1972
Special Clinical Fellow Award (Roswell Park Memorial Institute)	1977
The Honor Society of Phi Kappa Phi (University of South Florida)	1985
Best Scientific Presentation (Prevention 94, Atlanta, GA.)	1994
Center Directors Award for Outstanding Research (H. Lee Moffitt Cancer Center)	1995, 1997
Thomas C. Chalmers Award (VII Cochrane Colloquium, Rome Italy)	1999

PROFESSIONAL SOCIETIES:

Fellow, Royal College of Physicians (Edinburgh)

Fellow, American College of Physicians

Fellow, American College of Clinical Pharmacology

Fellow, American College of Preventive Medicine

Member, American Society of Clinical Oncology

Member, American Association for Cancer Research

Member, American Society of Hematology

Member, International Society on Thrombosis and Haemostasis

Member, Multinational Association of Supportive Care in Cancer

Member, International Society for Pharmacoeconomics and Outcomes Research

Member, Society for Clinical Trials

Member, Society for Medical Decision Making

Member, International Society for Health Economics

Member, Geriatric Oncology Consortium

Member, International Society of Geriatric Oncology

Member, International Society of Clinical Biostatistics

ACADEMIC POSITIONS:

Research Instructor in Medicine, State University of New York at Buffalo School of Medicine, Department of Medicine	1974-1977
Assistant Professor of Medicine, Department of Internal Medicine, University of South Florida College of Medicine	1977-1981
Associate Professor of Medicine, Department of Internal Medicine, University of South Florida College of Medicine	1981-1986
Associate Professor of Epidemiology and Biostatistics University of South Florida College of Public Health	1984-1986
Director, Division of Medical Oncology, Department of Internal Medicine, University of South Florida College of Medicine	1979-1993
Associate Chairman, Department of Internal Medicine University of South Florida College of Medicine	1990-1993
Chief, Section of Biostatistics and Epidemiology Division of Medical Oncology, Department of Internal Medicine	1982-2000
Professor of Medicine, Department of Internal Medicine University of South Florida College of Medicine	1986-2000

Professor of Epidemiology and Biostatistics University of South Florida College of Public Health	1986-2000
Medical Director, Executive MD/MPH Program University of South Florida College of Public Health	1996-2000
Member, Institute on Aging University of South Florida	1996-2000
Visiting Professor Medical Statistics Unit (Dr. _____) Department of Epidemiology and Population Health London School of Hygiene and Tropical Medicine University of London	1997-1998
Thomas Ordway Professor of Medicine Department of Medicine Albany Medical College	2000-2002
Cancer Center Director Albany Medical Center	2000-2002
Head, Division of Hematology/Oncology Department of Medicine Albany Medical College	2000-2002
Professor Department of Biometry and Statistics School of Public Health State University of New York at Albany	2000-2005
Member Center for Immunology and Microbial Disease Albany Medical College	2000-2002
Professor of Medicine with Unlimited Tenure (Teacher-Clinician-Scholar) University of Rochester School of Medicine and Dentistry	2002-2007
Associate Center Director for Health Services and Outcomes Research James P. Wilmot Cancer Center University of Rochester Medical Center	2002-2007
Duke University School of Medicine	2007 – present
Member, Duke Comprehensive Cancer Center	2007 – present
Senior Fellow, Duke Center for Clinical Health Policy Research	2007 – present

Fixed Term Graduate Faculty Appointment, Department of Health Policy and Administration,
 School of Public Health, University of North Carolina, Chapel Hill 2007 – present

RESEARCH GROUP MEMBERSHIP:

Principal Investigator, Southeastern Cancer Study Group, University of South Florida, H Lee Moffitt Cancer Center and Research Institute	1979-1987
Board of Directors, Cancer Care Network of Florida	1982-1986
Member, Head and Neck Intergroup	1980-1990
Principal Investigator, High Priority Studies Southwest Oncology Group, USF	1989-1992
Medical Oncology Liaison, Gynecology Oncology Group, University of South Florida	1987-1998
Cochrane Collaboration	
Member, Statistical Methods Working Group	1998-Present
Reviewer, Breast Cancer Review Group	1998-Present
Member, Economic Analysis Working Group	1998-Present
Member, Quality of Life Working Group	1999-Present
Senior Investigator, Albany Medical College	
Eastern Cooperative Oncology Group	1999-2002
Member Leukemia Committee	1999-2002
Member Health Behavior and Practice Committee	1999-2002
Member, Outcomes Subcommittee	1999-2002
Member, Aging Subcommittee	1999-2002
Member, Southwest Oncology Group	2002-2007
Member, Breast Cancer Committee	2002-2007
Member, Breast Committee Working Group	2002-2007
Member, Cancer Control Research Committee	2002-2007
Member, Cancer and Acute Leukemia Group B	2007-present

HOSPITAL AFFILIATION:

Chief, Section of Medical Oncology, James A. Haley Veterans Hospital, Tampa	1979-1989
Chief, Medicine Service, H. Lee Moffitt Cancer Center and	1985-1994

Research Institute at the University of South Florida, Tampa	1977-2000
Staff Hematologist, Tampa General Hospital, Tampa	
Staff Oncologist, James A. Haley Veterans Hospital, Tampa	1979-2000
Member, Medical Staff, H. Lee Moffitt Cancer Center, Tampa	1985-2000
Member, Medical Staff, Albany Medical Center, Albany, New York	2000-2002
Member, Medical Staff, University of Rochester Medical Center Strong Memorial Hospital, Rochester, New York	2002-2007
Member, James P Wilmot Cancer Center, Rochester, New York	2002-2007
Member, Medical Staff, Duke University Medical Center	2007-present
Member, Duke Comprehensive Cancer Center	2007-present

COMMITTEES:

Center/Hospital/University:

Member, Breast and Ovarian Oncology Program, Duke Comprehensive Cancer Center

Member, Cancer Prevention, Detection and Control Program, Duke Comprehensive Cancer Center

State/Regional:

Past Chairman, Board of Advisors, American Cancer Society - Lake's Region, Rochester, NY

Past Chairman, Medical Advisory Board, American Cancer Society - Lakes Region, Rochester, NY

Advisory Board, New York State Comprehensive Cancer Control Plan, New York State Department of Health, Albany, NY

National/International:

Board of Directors, Eastern Division, American Cancer Society, New York, New York
Prevention and Detection Workgroup
Medical and Scientific Relations Workgroup

Northeastern US Regional Advisor
Royal College of Physicians (Edinburgh)
American Joint Committee on Cancer

Melanoma Staging Committee

American Society of Clinical Oncology

- Member, Health Services Research Committee
 - Chairman, Methodology Subcommittee
 - Chairman, Lymphatic Mapping-Breast Cancer Guidelines Task Force
 - Chairman, VTE Prophylaxis in Cancer Task Force
 - Chairman, Lymphatic Mapping-Melanoma Guidelines Task Force
 - Member, White Blood Cell Growth Factor Guidelines Task Force
 - Member, Chemosensitivity Assay Task Force
 - Member PET Scan Technology Assessment
- Member, Cancer Education Committee
 - Health Services Research Track Liaison

Geriatric Oncology Consortium

- Member, Scientific Advisory Board
- Joint GOC/ONS Consensus Panel on Geriatric Oncology

National Comprehensive Cancer Network

- Member, Growth Factors Panel
- Member, Breast Cancer Screening and Diagnosis Panel

US Food and Drug Administration

- Member, Oncologic Drugs Advisory Committee (2007-2010)

EDITORIAL RESPONSIBILITIES:

Editor-In-Chief

- Cancer Investigation
 - Informa Healthcare
 - New York, New York, USA

Advisory Editor

- Cancer Treatment Reviews
 - Elsevier Science
 - Oxford, UK

Peer Review Editor

- Journal of Oncology Practice
 - American Society of Clinical Oncology
 - Alexandria, VA

Associate Editor

- Critical Reviews of Oncology and Hematology
 - Elsevier Science

Oxford, UK

Clinical Breast Cancer
Physician Education Resource, Dallas, TX, USA
Supportive Cancer Therapy
Cancer Information Group
Dallas, TX, USA

Current Cancer Therapy Reviews
Bentham Science Publishers Ltd.
San Francisco, CA USA

Reviewer: Cancer Research
Journal of Clinical Oncology (JCO)
The Lancet
Journal of the American Association (JAMA)
Journal of the National Cancer Institute (JNCI)
Cancer

PROFESSIONAL LISTINGS:

_____	_____
_____	_____
Who's Who in Frontier Science	1984-Present
_____	_____
Who's Who in Medicine and Healthcare	1996-Present
Who's Who in Cancer: Professionals and Facilities	1985-Present
Who's Who in Science and Engineering	2006-Present
Directory of Medical Specialists	1978-Present
Best Doctors in America	2003-Present
Top Doctors in America	2005-Present
Top Cancer Doctors	2006-Present

DISSERTATION COMMITTEES:

_____ Ph.D. (Medical Microbiology), "_____
_____" 1983

_____, M.S. (Nursing), "_____" 1985

_____, Ph.D. (Engineering), "_____
_____" 1988

_____, Ph.D. (Psychology), "_____
_____" 1989

_____, Ph.D. (Psychology), "_____
_____" 1989

_____ (Epidemiology and Biostatistics), M.P.H. _____
_____ 1996

_____ (Epidemiology and Biostatistics), Ph.D., "_____
_____" 1998

_____ (Epidemiology and Biostatistics), M.S.P.H.

_____ (Epidemiology and Biostatistics), Ph.D., University of South Florida College
of Public Health, Tampa, FL

_____ (Epidemiology and Biostatistics), M.P.H. University of South Florida College of
Public Health. Tampa, FL

_____ (Epidemiology), M.P.H. University of Rochester, Department of Community and
Preventive Medicine, Rochester, NY

_____ (Epidemiology), M.P.H. University of Rochester, Department of Community and
Preventive Medicine, Rochester, NY

_____ Ph.D. (Biostatistics), M.S. University of Rochester, Department of Biostatistics,
Rochester, New York.

_____ M.S. (Biostatistics), University of Rochester, Department of Biostatistics,
Rochester, New York

_____ Ph.D. (Pharmacoeconomics), University of Rochester, Department of
Community and Preventive Medicine, Rochester, New York

_____ Ph.D. University of North Carolina, School of Medicine Health, Department of Health Policy and Administration, Chapel Hill, North Carolina

GRANTS:

NIH 5 SO7 RR0-5749-05 Biomedical \$3,000.00; Liposome Incorporation of Specific and Non Specific Immunomodulators; period of time, 04-01-77 to 03-31-78.

Co-Investigator, amount \$251,000.00; funding source, National Cancer Institute; RFP NCI-CM-87154; Adjuvant Chemotherapy Trial in Head and Neck Squamous Carcinomas; period of time, 06-01-78 to 01-31-81.

Principal Investigator, amount \$3,000.00; funding source, NIH5SO7RR0574907; Development and Application of an In Vitro Human Tumor Cloning Assay; period of time, 09-01-79 to 08-31-80.

Principal Investigator, amount \$_____ ; funding source, Department of Health and Rehabilitative Services; Control of Nausea and Vomiting of Cancer Chemotherapy; period of time, 06-01-80 to 05-31-82.

Principal Investigator, amount \$116,333.00, funding source, Veterans Administration Cooperative Trial #188, James A. Haley Veterans Hospital; period of time, 06-01-80 to 05-31-85.

Co-Investigator, amount \$_____ funding source, American Lung Association of Florida, Lung Cancer and Environmental Exposures of Florida Residents; period of time, 06-01-86 to 05-31-87.

Co-Investigator, amount \$349,989, funding source, National Institutes of Health, Epidemiology of Lung Cancer in Nonsmoking women, period of time, 06-01-87 to 05-31-92.

Principal Investigator, _____ A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of _____ When Administered to patients with Neutropenia and Fever Following Cytotoxic Chemotherapy for Non-Hematological Malignancies, 9-1-93 to 12-31-97.

Co-Investigator, amount \$143,957, National Institutes of Health (R21 CA66553-03) Lymphatic Mapping and Accurate Staging of the Breast Cancer Patient, 06-01-95 to 05-31-00.

Principal Investigator, amount \$ _____ , The Economics of _____ period of time 1-1-97 to 03-03-00.

Co-Investigator, \$ _____ A Multicenter, Open-Label, Randomized Study of Three Schedules of _____ Therapy Followed by Weekly _____ Maintenance Therapy in Metastatic Breast Cancer Patients, period of time 5/10/99 to 7/1/01.

Co-Investigator, \$ _____ A Randomized, Double Blind, Multicenter, Comparative Trial of IV _____ vs IV _____ as an Adjunct to standard therapies in the treatment of _____, period of time, 6/9/99 to 7/1/01

Co-Investigator, amount \$243,327, funding source, US Department of Defense (#BC971295): Weight Gain in Breast Cancer Patients on Chemotherapy: Exploring Hormonal, Body Composition and Behavioral Mechanisms, period of time 7-1-98 to 6-30-01.

Co-Investigator, amount \$347,416, funding source: National Institutes of Health, Cognitive-Behavioral Aspect of Cancer-Related Fatigue (RO1 CA82822-01), period 07-01-88 to 06-30-02.

Co-Investigator, amount \$25,000, funding source: National Institutes of Health (R13 HS91366-01T) Conference Funding 3rd Annual Symposium on Evidence-Based Oncology, 1999

Principal Investigator, \$ _____ Funding source _____, Novel _____ in Cancer Chemotherapy, period 8/1/99 to 7/31/01

Principal Investigator, \$ _____ (three years), Funding Source: _____ Coordinating Center _____ Study Group, period 8/1/00 – 12/31/03

Co-Investigator, \$1,306,621 (two years), Funding source National Institutes of Health, Effect of Physicians Communication on Patient Accrual, period 04/01/01 – 03/31/03.

Principal Investigator, \$ _____ (phase 1), Funding source: Susan B Komen Foundation, Breast Cancer Chemoprevention: Outreach to Minority communities, period 4/01/01 – 3/30/02.

Principal Investigator, \$ _____ (one year), Funding Source: _____ Clinical and Economic Evaluation of _____, period 1/1/03 – 12/31/03.

Principal Investigator, \$ _____ Funding Source: _____, Patient Registry for _____ (Phase I), period 09/01/02 – 12/31/03

Principal Investigator, \$ _____ Funding Source: _____ Patient Registry for _____ (Phase II), period 01/01/04 – 12/31/04

Principal Investigator, \$ _____ (three years), Funding Source: _____ Coordinating Center _____ Study Group, period 01/1/04 – 12/31/07

Co-Investigator, \$ _____ (four years), Funding Source: American Cancer Society. Chemotherapy Risk Assessment Score for High-age patients: CRASH, period 07/01/03 – 12/31/08

Subcontractor, \$ 9,966,608/5 years; Department of Defense, Breast Cancer Centers of Excellence (A Neugut, Columbia University, PI); Racial Disparities in the Initiation and Intensity of Adjuvant Therapy for Breast Cancer; BC043120, period 04/01/05 – 03/30/10.

Principal Investigator, \$ _____ American Society of Clinical Oncology; Systematic Review of Preventive Strategies for Venous Thromboembolism in Cancer Patients, period 01/01/06 – 12/31/06

Principal Investigator, \$ _____ (2 years); Funding source: _____ Economic Analysis of _____, Early-Stage Breast Cancer, period: 01/01/05 – 12/31/06

Training Grants (Mentorship):
Cancer Education and Career Development Program-Control Research Training Curriculum: 4/01/04 – 3/30/09 (_____, PI)

Research Training in Geriatrics and Gerontology: 7/1/05 – 06/30/10 (_____, PI)

Clinical Research Training in Hematology and Oncology: 7/01/06 – 6/30/11 (_____, PI)

Principal Investigator, \$ _____ (three years), Funding Source: _____ Coordinating Center _____ Study Group, period 8/30/07 – 12/31/10

AREAS OF RESEARCH INTEREST

Design and Analysis of Clinical Trials of Novel Targeted Therapies
Clinical Pharmacology, Pharmacoeconomics and Health Technology Assessment
Research Synthesis and Evidence-Based Oncology
Mathematical and Statistical Risk Modeling and Individualized Medicine
International Health and Healthcare Outcomes in Developing Countries
Clinical and Public Health Decision Making
Environmental and Genetic Epidemiology
Patterns of Care, Disparities and Methods to Improve the Quality of Cancer Care Delivery
Cancer Treatment and Supportive Care in the Elderly

EDUCATIONAL PROGRAMS: (last 3 years)

Invited Lectures:

February 24, 2004 Evidence-Based Use of The Hematopoietic Growth Factors,
Medicine Grand Rounds, University of Rochester School of
Medicine and Dentistry, Rochester, NY

May 6, 2004	Reduced Dose Intensity in Curative Cancer Treatment, Grand Rounds, Herbert Irving Comprehensive Cancer Center, Columbia University College of Physicians and Surgeons, New York, New York
July 22-24, 2004	Bias in Screening and Diagnostic Research, Evidence Based Oncology, European School of Oncology, Antwerp, Belgium
July 22-24, 2004	Prognostic Markers and Predictive Models, Evidence Based Oncology, European School of Oncology, Antwerp, Belgium
August 11, 2004	Breast Cancer Update: Think Tank on Adjuvant Chemotherapy, New York, New York
August 26, 2004	Incidence and Predictors of Low Dose Intensity in Adjuvant Breast Cancer Chemotherapy. Grand Rounds, Clara Maass Medical Center, Belleville, NJ
August 27, 2004	Evidence Based Use of the Hematopoietic Growth Factors, Grand Rounds, East Orange VA Hospital, East Orange NJ
Asugust 27, 2004	Pharmacoeconomic Considerations in the Management of Cancer Patients. St Vincent's Comprehensive Cancer Center, New York, NY
September 3, 2004	Predicting Patients who are at risk of neutropenic complications and reduced dose intensity: a method to improve effectiveness. Appropriate Dose: Optimal Results, EORTC Infectious Disease Group, Barcelona, Spain
September 10, 2004	Management of Neutropenia and Anemia in Older Adults. Annual Meeting, Geriatric Oncology Consortium, Washington, DC
October 29, 2004	New Evidence in the Treatment of Anaemia and Neutropenia: Incorporating Guidelines and Data into Clinical Practice. Satellite Symposium. European Society of Medical Oncology Annual Meeting, Vienna, Austria
January 20, 2004	Evidence-Based Use of the Hematopoietic Growth Factors in Oncology, Oncology Grand Rounds, SUNY Upstate Medical Center, Syracuse, NY
February 22, 2005	Optimal clinical Use of the Myeloid Growth Factors. Oncology Grand Rounds, Medical College of Virginia, Richmond, VA

February 24, 2005	Evidence-Based Use of the Colony-Stimulating Factors. Hematological Malignancies Symposium, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC.
April 15, 2005	Gene Expression Profile Assays in Early-Stage Breast Cancer, Cancer Center Grand Rounds, Tufts University-New England Medical Center, Boston, MA
May 18, 2005	The Use of Gene Expression Profile Assays in Early-Stage Breast Cancer. Breast Cancer Conference. Georgetown University – Lombardi Cancer Center, Washington, DC
May 18, 2005	Gene Expression Profile Assays in Early-Stage Breast Cancer: Are They Ready for Prime Time? Breast Cancer Conference. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
May 19, 2005	Evidence-Based Use of the Hematopoietic Growth Factors. Medical Grand Rounds, Sinai Medical Center, Baltimore, MD
June 13, 2005	Chemotherapy Dose Intensity in Curable Malignancies: A Quality Indicator for Cancer Patient Care? Prevention Grand Rounds, Roswell Park Cancer Center, Buffalo, NY
June 27, 2005	Prophylactic Use of the Myeloid Growth Factors: From Evidence-Based Guidelines to Daily Practice, Zurich University Hospital, Zurich, Switzerland
June 27, 2005	Prophylactic Use of the Myeloid Growth Factors: From Evidence-Based Guidelines to Daily Practice, Zurich University Hospital, St Gallen University Hospital, St Gallen, Switzerland
June 28, 2005	Prophylactic Use of the Myeloid Growth Factors: From Evidence-Based Guidelines to Daily Practice, Kantonsspital Basel, Basel, Switzerland
June 28, 2005	Prophylactic Use of the Myeloid Growth Factors: From Evidence-Based Guidelines to Daily Practice, Kantonsspital Luzern, Luzern, Switzerland
July 12, 2005	Hurdles to Optimal Chemotherapy in Non-Hodgkin Lymphoma and Early-Stage Breast Cancer. Medizinische Klinik and Poliklinik II, Tuebingen, Germany
September 13, 2005	Evidence-Based Use of the Hematopoietic Growth Factors, Solid Tumor Oncology/Hematologic Malignancy Grand Rounds, Memorial Sloan Kettering Cancer Center, New York, NY

- October 3, 2005 The Myeloid Growth Factors: Evidence Basis for the 2005 Guidelines, Grand Rounds, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA
- October 26, 2005 Strategies for the Prevention of Fever and Neutropenia in Patients with Lymphoma. Lymphoma Grand Rounds, Princess Margaret Hospital, Toronto, Ontario, CA
- October 27, 2005 Strategies for the Prevention of Fever and Neutropenia in Cancer Chemotherapy Patients. Grand Rounds, St Michaels Hospital, Toronto, Ontario, CA
- November 2, 2005 Prophylactic Use of the Colony-Stimulating Factors, Chemotherapy Foundation Symposium XXIII: Innovative Cancer Therapy for Tomorrow, New York, NY
- December 9, 2005 Putting Anemia Guidelines Into Perspective. *Management of Anemia and Myelodysplastic Syndromes in Hematology/Oncology Practice*. American Society of Hematology Corporate Symposium 2005, Atlanta, GA
- December 13, 2005 A Risk Model for Chemotherapy-Induced Anemia in Cancer Patients. 47th Annual Meeting of the American Society of Hematology: Health Services: Hematologic Oncology Oral Presentation.
- January 20, 2006 The Promise and Challenges of Gene Expression Profile Assays in Early-Stage Breast Cancer, Translational Research Program Symposium: Proteomics & Genomics: The Future of Oncology, Radiation Therapy Oncology Group Annual Meeting, Miami, FL
- January-February 2006 An Introduction to Clinical Research Methods: Five part series for Advanced Subspecialty Residents, Division of Hematology/Oncology, Department of Medicine, University of Rochester, Rochester, NY
- April 26 2006 The Promise and Challenges of Gene Expression Profile Assays in Early-Stage Breast Cancer; Visiting Professor of Oncology, Royal Victoria Hospital, McGill University, Montreal, Quebec, Canada
- April 26, 2006 Chemotherapy Dose Intensity in Curable Malignancies: A Quality Indicator for Cancer Patient Care; Visiting Professor of Oncology, Montreal General Hospital, McGill University, Montreal, Quebec, Canada

- April 27, 2006 Selected and Targeted Application of the Myeloid Growth Factors: Progress Toward a Clinical Risk Model; Visiting Professor of Oncology, Hopital du Sacre Coeur de Montreal, McGill University, Montreal, Quebec, Canada
- May 13, 2006 New Clinical Guidelines and Evidence-Based Management of the Myeloid Growth Factors. Guidelines and Evidence Based Management of Neutropenia. Can we Improve? 37th Nordic Hematology Spring Meeting. Göteborg, Sweden
- May 15, 2006 Evidence Basis for Myeloid Growth Factor Guidelines. Oncology Grand Rounds, Karolinska Institute and Hospital, Stockholm, Sweden.
- September 14, 2006 The Risk and Management of Neutropenia in Cancer Patients Receiving Chemotherapy, Columbia University, Columbia-Presbyterian Hospital, New York, New York
- November 1, 2006 Emerging Supportive Care Strategies for the Hematologic Malignancies. Grand Rounds, Kimmel Cancer Center, Thomas Jefferson Medical University, Philadelphia, PA
- February 8, 2007 Who Defines Quality Cancer Care? Who Pays for Quality Cancer Care? 2nd Annual Community Oncology Conference, Washington, DC
- March 30, 2007 Health Economic Aspects of Anemia and Erythroid Stimulating Proteins. Anaemia and Cancer Therapy, European Organisation for Research and Treatment of Cancer, Rome Italy
- March 31, 2007 Erythroid Stimulating Proteins: Arguments for Early Intervention. Anaemia and Cancer Therapy, European Organisation for Research and Treatment of Cancer, Rome Italy
- July 13, 2007 The Role of ASCO and NCCN in Delivery of Quality Cancer Care. Oncology Highlights 2007" Updates from ASCO, Duke University, Durham, NC

TECHNICAL REPORTS:

Technical Report No. 237E. Analysis of EST 4479 Phase II Master Protocol for the Evaluation of New Agents in Patients with Acute Non-Lymphocytic Leukemia in relapse for the Eastern Cooperative Oncology Group, December 1981.
(publ. Am J Clin Oncol 1984;7:361-363, Am J Clin Oncol, 1984;7:471-473).

Technical Report No. 275E. Analysis of EST 2476 Chemotherapy of Acute Non-Lymphocytic Leukemia for the Eastern Cooperative Oncology Group, July, 1982.
Technical Report No. USF 8251. Analysis of the Antiemetic Study of Dexamethasone for the Tampa Bay Oncology Group, July, 1982.

Technical Report No. USF 8252. Analysis of the Antiarrhythmic Effects of Acebutolol and Propranolol in Patients with Premature Ventricular Contractions, for the Division of Cardiovascular Medicine, Department of Internal Medicine, USF, College of Medicine, Tampa, Florida, October, 1982. (publ Am J Cardiology, 1983).

Technical Report No. USF 8351. The Incidence and Outcome of Single Factor, Multifactorial, and Unexplained Infertility for BS Verkauf, Department of Gynecology, USF College of Medicine, January, 1983 (publication).

Technical Report No. USF 8481. Health Risk Associated With the Proposed Gardinier Gypsum Waste Stack at Progress Village, February, 1984.

Technical Report No. USF 8471. Analysis of Operative Mortality from Cardiovascular Surgery: 1975 to 1983, Morton F. Plant Hospital, Clearwater, Florida, October, 1984.

Technical Report No. USF 8472. Nutrition Factors for Cardiac Surgery for Dr. Leider, Clearwater, Florida.

Technical Report No. USF 8411. Nerve and Muscle vulnerability to Ischemia, for Jan K. Korthals (Publ J Neuro Sci, 1985;71:283-290).

Technical Report No. USF 8551. Dexamethasone as an Antiemetic in Cancer Chemotherapy, Part II for Robert Drapkin, M.D., Clearwater, Florida.

Technical Report No. USF 8651. Association of Endometriosis and Infertility for BS Verkauf, Department of Gynecology, USF College of Medicine, December, 1986.
(Publ J Fla. Med Assoc, 1987;74:671-675).

Technical Report No. USF 8851. Patterns of Care Study, Palms of Pasadena Hospital, St. Petersburg, Florida.

Technical Report No. USF 9251. Orthopedic Surgery Review, Morton Plant Hospital, Clearwater, Florida, 1992.

American Society of Clinical Oncology, Clinical Practice Guidelines Methodology Manual, 2005

MONOGRAPHS:

LYMAN GH: On the Nature, Origin and Evolution of Conceptual and Symbolic Processes, 1972.

LYMAN GH: Structural and Functional Changes in the Erythrocyte Membrane in Hemolytic Disease, 1972.

LYMAN GH: Erythropoiesis: Physiologic and Pharmacologic Control. (A Report submitted to the Education Department of Roswell Park Memorial Institute as partial fulfillment of the requirement for a year of clinical teaching in Medical Oncology), 1975.

LYMAN GH: Studies of the Membrane Action of Chemical Inducers of Murine Erythroleukemia Cell Differentiation. (A report submitted to the Education Department of Roswell Park Memorial Institute as partial fulfillment of the requirement for a year of clinical training in Medical Oncology), 1976.

Weiner RS, Vogel CL, LYMAN GH: Breast Cancer Treatment Update, 1979.

LYMAN GH: Infection Prophylaxis in Patients with Acute Myelogenous Leukemia, 1978.

LYMAN GH: Acute Myelogenous Leukemia Following Another Malignancy, 1979.

LYMAN GH: Unique Features of Small Cell Carcinoma of the Lung, 1979.

LYMAN GH: Crisis Relocation Planning: Uncivil Defense, 1983.

LYMAN GH, et al: Infection in Cancer Patients, 1987.

LYMAN GH: A Predictive Model for Neutropenia Associated with Cancer Chemotherapy, 1999.

PROFESSIONAL PUBLICATIONS:

BOOKS:

1. Sather MR, Weber CE, Jr., Preston D., LYMAN GH, Sleight SM: Cancer Chemotherapeutic Agents: Handbook of Clinical Data, GK Hall & co., 1980.

2. Preston D, LYMAN GH, Sather MR, Weber CE, Sleight SM: Cancer Chemotherapeutic Agents; Handbook of Clinical Data, 2nd edition, GK Hall & Co., 1982
3. Balducci L, LYMAN GH, Ershler WB: Geriatric Oncology, J.B. Lippincott, New York, 1992.
4. Balducci L, LYMAN GH, Ershler WB (eds): Comprehensive Geriatric Oncology, 1st Edition, Harwood Academic Publishers, London, 1998, pp 832.
5. Balducci L, LYMAN GH, Ershler WB, Extermann M (eds): Comprehensive Geriatric Oncology, 2nd Edition, Taylor & Francis Publishers, London, 2004 pp 878.
6. LYMAN GH, Burstein H (eds): Translational Therapeutic Strategies in Breast Cancer, Informa Healthcare, New York 2007; pp 321.
7. LYMAN GH, Crawford J (eds): Cancer Supportive Care: Advances in Therapeutic Strategies, Informa Healthcare, New York 2007 (in Press).
8. LYMAN GH (ed): The Oxford American Handbook of Oncology, Oxford University Press 2007 (in press).

BOOK CHAPTERS:

1. LYMAN GH, Williams CC, Dinwoodie WR: The Role of Lithium in Patients Receiving Cancer Chemotherapy in Lithium: Current Application in Science, Medicine and Technology, (ed. RO Bach), Wiley Interscience, 1985; 377-396.
2. LYMAN GH: Biostatistics in Professional Review for Tumor Registrars. Florida Tumor Registrars Association 1989; 151-162.
3. LYMAN GH: Biostatistics in Professional Review for Tumor Registrars. Florida Tumor Registrars Association 2005; 4th edition; 269-282.
4. LYMAN GH, Williams CC: Lithium Attenuation of Leukopenia Associated with Cancer Chemotherapy in Lithium and the Blood (VS Gallicchio ed.), Lithium Therapy Monographs, Vol 4, Karger of Basel, 1991; 30-45.
5. LYMAN GH: Proven Versus Dubious Treatment in Dubious Cancer Treatment, American Cancer Society, Port City Press, 1991: 1-5.
6. LYMAN GH: Decision Analysis: A Way of Thinking About Health Care in the Elderly in Geriatric Oncology, Balducci L, LYMAN GH, Ershler WB, (eds), J.B. Lippincott, New York, 1992, 8-19.

7. Balducci L, LYMAN GH: Adjunctive Therapy in Elderly Cancer Patients. In Geriatric Oncology, Balducci L, LYMAN GH, Erschler WB, (eds), J.B. Lippincott, New York, 1992,284-302.
8. Balducci L, LYMAN GH, Schapira DV: Trends in Prevention and Treatment of Breast Cancer in the Older Woman. In Facts and Research in Gerontology: Epidemiology and Aging. (BJ Vellas, JL Albarede, PJ Garry, eds) Springer Publishing, New York 1994, 179-192.
9. LYMAN GH, and Kuderer NM. Cancer Prevention, Detection and Control in Extending Your Lifespan: How You Can Live a Long and Healthy Life (Holt GA, McCrory MG, Norris GP, Sandler J eds) Mancorp Publishing 1996, 160-166.
10. LYMAN GH: Radon in Indoor Pollution and Health (EJ Bardana Jr and A Montanaro, eds.), Marcel Dekker, New York 1997: 179-199.
11. LYMAN GH, Kuderer NM: Incorporation of Quality of Life Considerations into Decision Models for the Use of Colony Stimulating Factors in Chemotherapy Patients at Risk for Febrile Neutropenia. In Febrile Neutropenia, (JA Klastersky, ed) Springer Verlag, Heidelberg, 1997: 17-22.
12. LYMAN GH: Essentials of Clinical Decision Analysis: A New Way to Think about Cancer and Age in Comprehensive Geriatric Oncology (Balducci L, Lyman GH, Erschler W, eds) 1st Edition, Harwood Academic Publishers, London, 1998, pp 7-17.
13. LYMAN GH, Kuderer NM: The Diagnosis and Treatment of Cancer in the Elderly: Cost Effectiveness Considerations in Comprehensive Geriatric Oncology (Balducci L, Lyman GH, Erschler W, ed) 1st Edition, Harwood Academic Publishers, London, 1998, pp 533-543.
14. Balducci L, Cox CE, Greenberg H, LYMAN GH, Miguel R, Karl R, Fabri PJ: Management of Cancer in the Older Person in Comprehensive Geriatric Oncology (Balducci L, Lyman GH, Erschler W, ed) 1st Edition, Harwood Academic Publishers, London, 1998, 363-368.
15. Altman DG, LYMAN GH: Methodological Challenges in the Evaluation of Prognostic Factors in Breast Cancer in Prognostic Variables in Node-Negative and Node Positive Breast Cancer (G Gasparini, ed) Kluwer Academic Publishers, 1998, 379-393.
16. LYMAN GH: Methodological Issues Related to Health Economic analysis in controlled clinical trials. Handbook of Statistics in Clinical Oncology (J Crowley, ed), Marcel Dekker, 2001; 291-320.
17. LYMAN GH: Essentials of Clinical Decision Analysis: A New Way to Think about Cancer and Age in Comprehensive Geriatric Oncology (Balducci L, Lyman GH, Erschler W, eds) 2nd Edition, Taylor & Francis Publishers , London, 2004: 11-25.

18. LYMAN GH, Kuderer NM: The Diagnosis and Treatment of Cancer in the Elderly: Cost Effectiveness Considerations in Comprehensive Geriatric Oncology (Balducci L, Lyman GH, Erschler W, ed) 2nd Edition, Taylor & Francis Publishers , London, 2004: 510-524..
19. Balducci L, Cox CE, Greenberg H, LYMAN GH, Miguel R, Karl R, Fabri PJ: Management of Cancer in the Older Person in Comprehensive Geriatric Oncology (Balducci L, Lyman GH, Erschler W, ed) 2nd Edition, Taylor & Francis Publishers, London, 2004: 391-398.
20. LYMAN GH, Kuderer NM: Economics of Hematopoietic Growth Factors in Hematopoietic Growth Factors in Oncology: Basic Science and Clinical Therapeutics (G Morstyn, M Foote and GJ Lieschke, eds), Humana Press Inc, Totowa, New Jersey, 2004: 409-443.
21. LYMAN GH, Kuderer NM: Febrile Neutropenia in Supportive Care Handbook (A Berger, ed); CMP Healthcare Media LLC: Manhasset, New York, 2005: 23-54.
22. Kuderer NM and LYMAN GH: Gene Expression Profile Assay Performance as a Predictor of Recurrence-Free Survival in Early-Stage Breast Cancer Early-Stage Breast Cancer in Translational Therapeutic Strategies in Breast Cancer, Lyman GH, Burstein H (eds): Informa Healthcare, New York 2007; 137-145.
23. Cosler LE and LYMAN GH: An Economic Analysis of the Impact of a 21-Gene RT-PCR Assay on Treatment Decisions in Early-Stage Breast Cancer in Translational Therapeutic Strategies in Breast Cancer, Lyman GH, Burstein H (eds): Informa Healthcare, New York 2007; 147-157.
24. LYMAN GH: Neutropenia in The Encyclopedia of Cancer (M Schwab, ed), 2nd edition, Springer Verlag GmbH, Heidelberg, 2007.
25. LYMAN GH, Kuderer NM: Improving outcomes from cancer-associated VTE: lessons from the ASCO guidelines in Cancer Associated Thrombosis, Khorana A, Francis CF, (eds): Informa Healthcare, New York 2007 (in press).
26. LYMAN GH: Clinical Prediction Models for Guiding the Use of Supportive Care. In Cancer Supportive Care: Recent Advances (Lyman GH, Crawford J (eds):, Informa Healthcare, New York 2007 (in press).
27. Dale DG, Crawford J, LYMAN GH: Neutropenia and Its Complications. In Cancer Supportive Care: Recent Advances (Lyman GH, Crawford J (eds):, Informa Healthcare, New York 2007 (in press).
28. LYMAN GH, Glaspy J: Early Intervention with rhu Erythropoietin for Chemotherapy-Induced Anemia. In Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology –

Scientific and Clinical Aspects of Anemia in Cancer, 2nd edition, Springer-Verlag, Wien, New York, 2007 (in press).

PROFESSIONAL PERIODICALS:

Peer-Reviewed Publications

1975

1. Preisler HD, LYMAN GH: Differentiation of Erythroleukemia Cells In Vitro: Properties of Chemical Inducers. *Cell Differentiation*, 1975;4:179-185.

1976

2. Preisler HD, Bjornsson S, Mori M, LYMAN GH: Inducers of Erythroleukemia Cell Differentiation *In Vitro*: Effects of *In Vivo* Administration, *Brit J Cancer*, 1976; 33:634-635.
3. LYMAN GH, Preisler HD, Papahadjopoulos D: Membrane Action of Dimethylsulfoxide and Other Chemical Inducers of Friend Leukemic Cell Differentiation. *Nature*. 1976;262:361-363.
4. LYMAN GH, Papahadjopoulos D, Preisler HD: Phospholipid Membrane Stabilization by Dimethylsulfoxide and Other Inducers of Friend Leukemia Cell Differentiation. *Biochem et Biophys Acta*, 1976; 448:460-473.

1977

5. Preisler HD, LYMAN GH: Acute Myelogenous Leukemia Subsequent to Therapy for a Different Neoplasm: Clinical Features and Response to Therapy. *Am J Hematology*, 1977;3:209-218.

1978

6. LYMAN GH, Bettigole R, Robson E, Ambrus JL, Urban H: Fibrinogen Kinetics in Patients with Neoplastic Disease. *Cancer*, 1978;41: 1113-1122.
7. LYMAN GH, Hartmann RC, Saba HI, Preston D, Shukovsky L, Jensen R, Knight M: Combination Chemotherapy and Radiation Therapy of Undifferentiated Small Cell Bronchogenic Carcinoma. *South Med J*, 1978;71: 519-524.

1979

8. LYMAN GH, Preisler HD: Carcinoma of Unknown Origin: The Need for Improved Management. *J Medicine*, 1978;9:445-459.

1980

9. LYMAN GH, Williams CC, Preston D: The Use of Lithium Carbonate to Reduce Infection and Leukopenia During Systemic Chemotherapy. *N Engl J Med*, 1980;302:257-259.

10. LYMAN GH: Adjunctive Agents in Systemic Chemotherapy. *Comprehensive Therapy*, 1980;6: 16-25.
11. LYMAN GH, Williams CC, Dinwoodie WR, Preston: The Effect of Lithium Carbonate Administration in Patients with Advanced Small Cell Bronchogenic Carcinoma Receiving Combination Chemotherapy and Radiotherapy, *Advances in Experimental Biology and Medicine*, 1980; 127:207-229.

1981

12. LYMAN GH, Williams CC, Preston D, Goldman A, Dinwoodie WR, Saba H, Hartmann R, Jensen R, Shukovsky L: Lithium Carbonate in Patients with Small Cell Lung Cancer Receiving Combination Chemotherapy. *Am J Med*, 1981;70: 1222-1229.

1982

13. LYMAN GH: The Medical and Public Health Consequences of Nuclear War on the State of Florida, *J. Fla Med Assoc*, 1982;69: 997-1001.

1984

14. Cassileth PA, LYMAN GH, Bennett JM, Glick JH, Oken MM: High Dose AMSA Therapy on Relapsed and Refractory Adult Acute Non Lymphocytic Leukemia – A Phase II Study, *Am J Clin Oncol*, 1984;7:361-363.
15. Bennett JM, LYMAN GH, Cassileth PA, Glick JH, Oken MM: A Phase II Trial of VP 16-213 in Adults with Refractory Acute Myeloid Leukemia – An Eastern Cooperative Oncology Group Study, *Am J Clin Oncol*, 1984;7:471-473.
16. LYMAN GH, Williams CC, Dinwoodie WR, Schocken DD: Sudden Death in Cancer Patients Receiving Lithium, *J Clin Oncology*, 1984;2:1270-1276.

1985

17. LYMAN GH, Lyman CG, Johnson W: Association of Leukemia with Radium Groundwater Contamination, *J Am Med Assoc*, 1985;254:621-626.
18. Marsden DE, Cavanagh D, Wisniewski BJ, Roberts WS, LYMAN GH: Factors Affecting the Incidence of Infectious Morbidity After Radical Hysterectomy, *Am J Obst Gyn*, 1985;152: 817-821.

1986

19. Dinwoodie WR, Bartolucci AA, LYMAN GH, Velez-Garcia E, Martello OJ, Sarma PR: A Phase II Evaluation of Cisplatin, Belomycin and Vindesine in Advanced Squamous Cell Carcinoma of the Esophagus. A Southeastern Cancer Study Group Trial, *Cancer Treat Rep*, 1986;70:267-270.

20. Roberts WS, Bryson SCP, Cavanagh D, Roberts VC, LYMAN GH: Peritoneal Cytology and Invasive Carcinoma of the Cervix, *Gynecol Oncol*, 1986;24:331-336.
21. Limberg MG, Margo CE, LYMAN GH: Eosinophils in Corneas Removed by Penetrating Keratoplasty, *Br J Ophthalmol*, 1986;70:343-346.
22. Schocken D, Robinson B, LYMAN GH: Digitalis Use in A Retirement Community: Results of A Systematic Study. *J Am Geriatr Soc*, 1986;34:504-506.
23. Stockwell HG, LYMAN GH: Impact of Smoking and Smokeless Tobacco on the Risk of Cancer of the Head and Neck, *Head and Neck Surgery*, 1986;9:104-110.
24. Cintron G, Medina R, Reyes A, LYMAN GH: Dental Procedures in Patients with Recent Uncomplicated Myocardial Infarction, *Arch Int Med*, 1986;146:2203-2204.

1987

25. Yangco BG, DeLerma C, LYMAN GH, Price D: Clinical Study Evaluation Efficacy of Praziquantel in Clonorchiasis, *Antimicrobial Agents in Chemotherapy*, 1987;31:135-138.
26. LYMAN GH, Vogler WR, Raney M: Continuous Infusion Diaziquone in Acute Myeloid Leukemia: A Southeastern Cancer Study Group Trial, *Cancer Treat Rep*, 1987;71:309-310.
27. Roberts WS, Cavanagh D, Bryson SCP, LYMAN GH, Hewitt S: Major Morbidity Following Pelvic Exenteration: A Seven Year Experience, *Obstet and Gyn*, 1987;69:617-621.
28. Stockwell HG, LYMAN GH, Hopes S: Cigarette Smoking and the Risk of Female Reproductive Cancers. *Am J Obst Gyn*, 1987;157:35-40.
29. Head and Neck Contracts Program: Adjuvant Chemotherapy for Advanced Head and Neck Squamous Carcinoma: *Cancer*, 1987;60:301-311.

1988

30. Hoffman MS, Roberts WS, Bryson SCP, Kavanagh JJ, Cavanagh D, LYMAN GH: Treatment of Recurrent and Metastatic Cervical Cancer With Cisplatin, Doxorubicin and Cyclophosphamide. *Gynecol Oncol*, 1988;29:32-36.
31. Wickstrom EL, Bacon TA, Gonzales A, Freeman DL, LYMAN GH, Wickstrom E: Human Promyelocytic Leukemia HL-60 Cell Proliferation and c-myc Expression Inhibited by An Antisense Pentadecadeoxynucleotide Targeted Against c-myc mRNA, *Proc Natl Acad Sci USA*, 1988;85:1028-1032.
32. Clark PI, Glasser SP, LYMAN GH, Drug-fite J, Root A: Relation of Results of Exercise Stress tests in Young Women to Phases of the Menstrual Cycle. *Am J Cardio*, 1988;61:197-199.

33. Weston MW, Glasser SP, Stover DJ, LYMAN GH: Clinical Assessment of Beta Blockade. *Clin Cardio*, 1988;11:311-316.
34. Stockwell HG, LYMAN GH, Waltz J, Petus JT: Lung Cancer in Florida: Risks Associated with Residence in the Central Florida Phosphate Mining Areas. *Am J Epi*, 1988;128:78-84.
35. Multicenter Study Group: Technetium-Labeled Monoclonal Antibodies for Imaging Metastatic Melanoma: Results of a Multicenter Trial. *Sem Oncol*, 1988;15:608-618.

1989

36. Morris DJ, LYMAN GH, Muus C: Impetiginous Lesions in Recurrent AML. *Hospital Practice*, 1989;24:153-156.
37. Wickstrom EL, Bacon TA, Gonzalez A, LYMAN GH, Wickstrom E: Anti-c-Myc DNA Increased Differentiation and Decreases Colony Formation by HL-60 Cells. *In Vitro Cellular and Developmental Biology*, 1989;24:297-302.
38. Hoffman MS, Roberts WS, Cavanagh D, Praphat H, Solomon P, LYMAN GH: Treatment of Recurrent and Metastatic Endometrial Cancer with Cisplatin, Doxorubicin, Cyclophosphamide and Megestrol Acetate. *Gyn Oncology*, 1989;35:75-77.
39. Roberts WS, Cavanagh D, Roberts VC, Hewitt S, LYMAN GH: Wound Hematoma: Prophylaxis with Topical Thrombin. *South Med J*, 1989;82:607-609.
40. Goldschmid S, Boyce HW, Brown JI, Brady PG, Nord HJ, LYMAN GH: A new Objective Measurement of Esophageal Lumen Patency. *Am J Gastroenterology*, 1989;84:1255-1258.

1990

41. Schapira DV, Kumar NB, LYMAN GH, Cox CE: Abdominal Obesity and Breast Cancer Risk. *Ann Int Med*, 1990;112:182-186.
42. Schapira DV, Kumar NB, LYMAN GH, McMillan SC: The Value of Current Nutrition Information. *Prevent Med*, 1990;19: 45-53.
43. Morris DJ, Muus C, LYMAN GH: Abdominal Pain and a Pelvic Mass, *Hospital Practice*, 1990;25: 80-88.
44. Hoffman M, Molpus K, Roberts WS, LYMAN GH, Cavanagh D: Tubo Ovarian Abscess in Postmenopausal Women. *J Reprod Medicine*, 1990;35:525-528.
45. Morris DJ, LYMAN GH, Muus C: Extramedullary Relapse of Acute Myeloid Leukemia at Phlebotomy and Bone Marrow Sites. *Hematology Reviews*, 1990;4:229-235.

46. Schapira DV, Kumar NB, LYMAN GH: Serum Cholesterol Reduction with Tamoxifen. *Breast Cancer Res and Treatment*. 1990; 17:3-7.

1991

47. Johnson DH, Ruckdeschel JC, Keller JH, LYMAN GH, Kallas GJ, MacDonald J, DeConti RC, Lee J, Ringenberg QS, Patterson WP, Lazarows HM, Lockich J: A Randomized Trial to Compare Intravenous and Oral Etoposide in Combination with Cisplatin for the Treatment of Small-Cell Lung Cancer. *Cancer*, 1991;67:245-249.
48. Schapira DV, Kumar NB, LYMAN GH, Cox CE: Obesity and Body Fat Distribution and Breast Cancer Prognosis. *Cancer*, 1991;67:523-528.
49. The Department of Veterans Affairs Laryngeal Cancer Study Group: Induction Chemotherapy plus Radiation Compared with Surgery plus Radiation in Patients with Advanced Laryngeal Cancer. *N Engl J Med*, 1991;324:1685-1690.
50. Schapira DV, Kumar NB, LYMAN GH: Obesity, Body Fat Distribution and Sex Hormones in Breast Cancer Patients. *Cancer*, 1991;67:2215-2218.
51. Schapira DV, Kumar NB, LYMAN GH: Estimate of Breast Cancer Risk Reduction with Weight Loss. *Cancer*, 1991;67:2622-2625.
52. Crawford J, Ozer H, Stoller R, Johnson D, LYMAN GH, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G, Smith R, Gradishar W, Yaharda A, Vincent M, Stewart M, Glaspy J: Reduction in the Incidence of Chemotherapy-Induced Febrile Neutropenia in Patients with Small Cell Lung Cancer. *N Engl J Med*, 1991;325:164-170.
53. Schapira DV, Kumar NB, LYMAN GH, Cavanagh D, Roberts WS, LaPolla J: Upper-Body Fat Distribution and Endometrial Cancer Risk. *J Am Med Assoc*, 1991;266:1808-1811.
54. Balducci L, Schapira DV, Cox CE, Greenberg HM, LYMAN GH: Breast Cancer of the Older Woman: An Annotated Review. *J Am Geriatric Society*, 1991;39:1113-1123.
55. Schapira DV, Kumar NB, LYMAN GH, Baile WF: The Effect of Duration of Intervention and Locus of Control on Dietary Change. *Am J Prev Med*, 1991;7:341-347.
56. Fiorica JV, Roberts WS, Hoffman MS, Barton DPJ, Finan MA, LYMAN GH, Cavanagh D: Concentrated Albumin Infusion as an Aid to Postoperative Recovery After Pelvic Exenteration. *Gyn Oncology*, 1991;43:265-269.
57. Schapira DV, Kumar NB, LYMAN GH: The Effect of Tamoxifen on Serum Cholesterol. Synopsis. *J Am Dietetic Assoc*. 1991;91:982.

1992

58. Jacobs C, LYMAN GH, Velez-Garcia E, Sridhar K, Knight W, Hochster H, Goodnough L, Mortimer J, Einhorn L, Schacter L, Cherng N, Dalton T, Burroughs J, Rozenzweig M: a Phase III Randomized Study Comparing Cisplatin and Fluorouracil as Single Agents and in Combination for Advanced Squamous Cell Carcinoma of the Head and Neck. *J Clin Oncol*, 1992;10:257-263.
59. Fields K, Eifenbein G, Saleh R, Zorsky P, Janssen W, Perkins J, Saleh T, Piazza J, Kronish L, Machak M, LYMAN GH: Ifosfamide, Carboplatin, and Etoposide in Combination for Induction and High-Dose Chemotherapy: Focus on Breast Cancer and Lymphoma. *Hematological Oncology*, 1992;10:61-74.
60. Stockwell HG, Goldman AL, LYMAN GH, Noss CI, Armstrong AW, Pinkham PA, Candelora EC, Brusa MR: Environmental Tobacco Smoke and Lung Cancer Risk in Nonsmoking Women. *J Natl Cancer Inst*, 1992;84:1417-1422.
61. LYMAN GH, Spiers ASD: Current Cancer Therapy: An Overview. *Hematological Oncology*, 1992;10:3-6.
62. LYMAN GH: Risk Factors for Cancer. *Primary Care I. Cancer Epidemiology, Prevention and Screening*, 1992; 19: 465-479.

1993

63. LYMAN GH, Lyman CG, Sanderson RA, Balducci L: Decision Analysis of Hematopoietic Growth Factor Use in Patients Receiving Cancer Chemotherapy. *J Natl Cancer Inst*. 1993;85:488-493.
64. Schapira DV, Kumar NB, LYMAN GH: Variation in Body Fat Distribution and Breast Cancer Risk in the Families of Patients with Breast Cancer and Control Families. *Cancer*, 1993;71:2764-2768.
65. Reintgen D, Cox C, Greenberg H, Behnke R, Nicosia S, Berman B, Clark H, LYMAN GH: The Medical Legal Implications of Following Mammographic Breast Masses. *American Surgeon*, 1993;59:99-105.
66. Reintgen D, Berman G, Cox C, Baekey P, Nicosia S, Greenberg H, LYMAN GH, Clark RA: The Anatomy of Missed Breast Cancers, *Surg Oncol*, 1993;2:65-75.
67. Balducci L, Benson K, LYMAN GH, Sanderson R, Fields K, Ballester OF, Eifenbein GJ: Cost Effectiveness of White Cell Reduction Filters in Treatment of Adult Acute Myelogenous Leukemia. *Transfusion*, 1993;33:665-670.
68. LYMAN GH, Balducci L: Overestimation of Test Effects in Clinical Judgment. *J of Cancer Education*, 1993;8:297-307.
69. Ward TT, Thomas RG, Fye CL, et al, including LYMAN GH: Trimethoprim-Sulfamethoxazole Prophylaxis in Granulocytopenic Patients with Acute Leukemia –

Evaluation of Serum Antibiotic Levels in a Randomized, Double-Blind, Placebo-Controlled Department Of Veterans Affairs Cooperative Study. *Clinical Infectious Diseases* 1993;17:323-332.

1994

70. Balducci L, Cox C, Greenberg H, LYMAN GH, Miguel R, Karl R, Fabri PJ: Management of Cancer in the Older Aged Person. *Cancer Control*, 1994;1:132-137.
71. Schapira DV, Wolf PA, Kumar NB, Anderson JB, Aziz NM, LYMAN GH, Swanson M: The Effect of Weight Loss on Estimated Breast Cancer Risk and Sex Hormone Levels. *Oncology Reports*, 1994;1:613-617.
72. Ballester OF, Moscinski LC, LYMAN GH, Chaney JB, Saba HI, Spiers ASD, Klein C: Interleukin-6: A Growth Factor or a Differentiation Factor for Multiple Myeloma. *Blood*, 1994;83:1903-1908.
73. Austin PF, Cruse CW, LYMAN GH, Schroer K, Glass F, Reintgen DS: Age as a Prognostic Factor in the Malignant Melanoma Population. *Annals Surg Oncol*, 1994;1:487-494.
74. LYMAN GH, Balducci L: The Effect of Changing Disease Risk on Clinical Reasoning. *Journal Gen Int Med*, 1994;9:488-495.
75. Spaulding MB, Fischer SG, Wolf GT and The Department of Veterans Affairs Cooperative Laryngeal Salvage Study Group: Tumor Response, Toxicity and Survival After Neoadjuvant Organ-Preserving Chemotherapy for Advanced Laryngeal Carcinoma. *J Clin Oncology*, 1994;12:1592-1599.
76. Arango HA, Kalter CS, Decesare SL, Fiorica JV, LYMAN GH, Spellacy WN: Management of Chemotherapy in a Pregnancy Complicated by a Large Neuroblastoma. *Obstet Gyn*, 1994;84:665-668.
77. Reintgen D, Cruse CW, Berman C, Fenske N, Glass F, Schroer K, Heller R, Ross M, LYMAN GH, Seigher HF, Balch C: The Orderly Progression of Melanoma Nodal Metastasis. *Annals Surgery*, 1994;220:759-767.

1995

78. Godellos CV, Berman CG, LYMAN GH, Gruse CW, Heller R, Lang XI, Glass F, Fenski N, Massie J, Puleo C, Rossim, Reintgen DS: The Identification and Mapping of Melanoma Regional Nodal Metastases: Minimally invasive surgery for the diagnosis of Nodal Metastases. *The American Surgeon*, 1995;61:2:97-101.
79. Kumar NB, LYMAN GH, Alten K, Cox CE, Shapira DV: Timing of Weight Gain and Breast Cancer Risk, *Cancer*, 1995;76:243-249.
80. Werner H, Phupanich S, LYMAN GH: Increasing Incidence of Primary Brain Tumors in the Elderly in Florida. *Cancer Control*, 1995;2:309-314.

81. Berman B, LYMAN GH, Balester OF, Sanderson RA, Spiers ASD: Therapeutic Use of Granulocyte Colony Stimulation Factor After Induction Chemotherapy in High Risk Acute Nonlymphocytic Leukemia: An Analysis of Clinical Practice. *Hematology Reviews* 1995;9:213-221.
82. Reintgen D, LYMAN GH, Yeatman T, Cox C: Non-Operative Observation of Mammographic Abnormalities: Medical Legal Implications. *The Breast Journal*, 1995;1:262-267.
83. Werner H, Phupanich S, LYMAN GH: The Increasing Incidence of Malignant Glioma and Primary Central Nervous System Lymphoma in the Elderly. *Cancer*, 1995;76:1634-1642.
84. LYMAN GH, Balducci L: A Cost Analysis of Hematopoietic Colony-Stimulating Factors. *Oncology* 1995;9:85-91.

1996

85. Melliores G, Albertini J, Berman C, Heller R, Messina J, Glass F, Cruse W, Rappaport D, Puleo C, Fenski N, Petsofglov C, DeConti R, LYMAN GH: The Tumor Biology of Melanoma Nodal Metastasis. *The American Surgeon*, 1996;62:81-88.
86. Albertini JJ, Cruse CW, Rappaport D, Wells SK, DeConti R, Berman CG, Jared K, Messina J, LYMAN GH, Glass F, Fenske N, Reintgen DS: Intraoperative Radiolymphoscintigraphy Improves Sentinel Lymph Node Identification In Melanoma Patients. *Ann Surgery*, 1996;223:217-224.
87. Benson K, Balducci L, Milo K, Heckel L, LYMAN GH: Patients' Attitudes Regarding Out-of-Hospital Blood Transfusion. *Transfusion* 1996;36:140-143.
88. LYMAN GH, Lyman S, Balducci L, Kuderer N, Reintgen D, Harris J, Cox C, Baekey P, Greenberg H, Horton J: Age and the Risk of Breast Cancer Recurrence. *Cancer Control* 1996;3:421-427.
89. Extermann M, Balducci L, LYMAN GH: Optimal Duration of Adjuvant Tamoxifen Treatment in Elderly Breast Cancer Patients: Influence of Age, Comorbidities and Various Effectiveness Hypotheses on Life Expectancy and Cost. *Breast Diseases*, 1996;9: 327-339.
90. Albertini JJ, LYMAN GH, Cox C, Yeatman T, Balducci L, Ku N, Shivers S, Berman C, Wells K, Rappaport D, Shons A, Horton J, Greenberg H, Nicosia S, Clark R, Cantor A, Reintgen D: Lymphatic Mapping and Sentinel Node Biopsy in the Breast Cancer Patient. *J Am Med Assoc*; 1996;276:1818-1822.

91. Miliotes G, LYMAN GH, Cruse CW, Puleo C, Albertini J, Rappaport D, Glass F, Fenski N, Soriano T, Cuny C, VanVoorhis N, Reintgen D: The Evaluation of New Patient Tumor Markers for Melanoma. *Ann Surgical Oncology*, 1996;3:558-563.
92. Webster J, Kuderer N, LYMAN GH: The Use of G-CSF to Sustain Dose Intensity in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Pilot Study. *Cancer Control*, 1996;3: 519-523.
93. Balducci L, LYMAN GH, Fabri PJ: Management of Cancer in the Aged. *Comp Therap* 1996;22: 88-93.

1997

94. LYMAN GH, Kuderer NM, Lyman SL, Cox C, Reintgen D: The Importance of Race on Survival with Breast Cancer. *Annals Surgical Oncol* 1997;4:80-87.
95. Yeatman TJ, LYMAN GH, Smith SK, Reintgen DS, Cantor AB, Cox CE: Bilaterality and Recurrence Rates for Lobular Breast Cancer: Considerations for Treatment. *Ann Surg Oncol* 1997;4:198-202.
96. Kumar NB, Allen K, Cantor A, Cox CE, Greenberg H, Shah S, LYMAN GH: Weight Gain Associated with adjuvant Tamoxifen Therapy in Stage I and II Breast Cancer: Fact of Artifact: *Breast Cancer Research and Treatment*, 1997;44:135-143.
97. Reintgen D, Albertini J, Milliotis g, Marsburn J, Cruse W, Rappaport D, Berman C, Glass F, Fenske N, Einstein AB, LYMAN GH: Investment in New Technology Research Can Save Future Health Care Dollars. *J Fla Med Assoc*, 1997;84:175-181.
98. Reintgen D, Joseph E, LYMAN GH, Yeatman T, Balducci L, Ku NN, Berman C, Shons A, Wells K, Horton J, Greenberg H, Nicosia S, Clark R, Shivers S, Li W, Wang X, Cantor A, Cox C: The Role of Selective Lymphadenectomy in Breast Cancer. *Cancer Control*, 1997;4:211-219.
99. LYMAN GH, Kuderer NM, Lyman SL, Debus M, Minton S, Balducci L, Horton J, Reintgen D, Cox C: Menopausal Status and the Impact of Early Recurrence in Breast Cancer Survival. *Cancer Control*, 1997;4: 335-341.
100. Wells K, Rapaport DP, Cruse CW, Payne W, Albertini J, Berman C, LYMAN GH, Reintgen DS: Sentinel Node Biopsy in Melanoma of the Head and Neck. *Plastic and Reconstructive Surgery*, 1997;100:591-594.
101. LYMAN GH; Kuderer NM: A Primer for Evaluating Clinical Trials. *Cancer Control*, 1997;4: 413-418.
102. LYMAN GH, Kuderer NM: Basic Population and Cancer Genetics and Their Use in the Assessment of Cancer Risk. *European J Cancer*. 1997;33:2160-2166.

103. LYMAN GH, Kuderer N, Lyman SL: Cancer Epidemiology: Genetic and Environmental Risk Factors. *Mahidol Journal*, 1997;4:33-39.
104. Cox CE, Hyacinthe M, Gonzalez R, LYMAN GH, Reintgen D, Ku NN, Miller MS, Greenberg, H, Nicosia SV: Cytologic Evaluation of Lumpectomy margins in Patients with Ductal Carcinoma in-situ: Clinical Outcome. *Ann Surg Oncol*, 1997;4:644-649.
105. Balducci L, LYMAN GH: Cancer in the Elderly. Epidemiologic and Clinical Implications. *Clin Geriatr Med*. 1997; 13: 1-14.
106. Joseph E, LYMAN G, Messina et al: Tumour Markers in Malignant Melanoma: A Review. *Tumour Marker Update* 1997; 9: 157-163.

1998

107. Extermann M, Overcash J, LYMAN GH, Parr J, Balducci L: Co-morbidity and Functional Status are Independent in Older Cancer Patients. *J Clin Oncol* 1998;16:1582-1587.
108. Broeckel J, Jacobson PB, Horton J, Balducci L, LYMAN GH: Characteristics and Correlates of Fatigue Following Chemotherapy for Breast Cancer. *J Clin Oncol*, 1998;16:1689-1696.
109. Cox CE, Pendas S, Cox JM, Joseph E, Shons AR, Yeatman T, Ku NN, LYMAN GH, Berman C, Hadad F, Reintgen DS: Guidelines for Sentinel Node Biopsy and Lymphatic Mapping of Patients with Breast Cancer. *Ann Surg* 1998;227:645-653.
110. Hann DM, Jacobson PB, Azzarello LM, Martin SC, Curran SL, Fields K, Greenberg H, LYMAN GH: Measurement of Fatigue in Cancer Patients: Development and Validation of the Fatigue Symptom Inventory. *Quality of Life Research*. 1998; 7:301-310.
111. Brobeil A, Berman C, Cruse CW, DeConti R, Cantor A, LYMAN GH, Rappaport D, Joseph E, Wells K, Reintgen DS: Survival Advantage for Patients with Extremity Confined Recurrent Melanoma Treated with Hyperthermic Isolated Limb Perfusion. *Ann Surg Oncol*, 1998;5:376-383.
112. LYMAN GH, Kuderer N, Greene J, Balducci L: The Economics of Febrile Neutropenia: Implications for the Use of Colony-Stimulating Factors. *Eur J Cancer* 1998; 34: 1857-1864.
113. LYMAN GH, Kuderer N, Balducci L: Cancer Care in the Elderly: Cost and Quality of Life Considerations. *Cancer Control*. 1998; 5: 347-354.
114. Joseph E, Hyacinthe M, LYMAN GH, Busch C, Reintgen DS, Cox CE: Evaluation of an Intensive Strategy for Follow-up and Surveillance of Early Breast Cancer. *Ann Surg Oncol*. 1998;5:522-528.

115. Shivers SC, Wang X, Li W, Joseph E, Messina J, Glass F, DeConti R, Cruse CW, Berman C, Fenske NA, LYMAN GH, Reintgen DS: Molecular Staging of Malignant Melanoma: Correlation with Outcome. *J Am Med Assoc*, 1998;280: 1410-1415.
116. Benson K, Agosti SJ, LYMAN GH, Pow-Sang JM, Saba HI, Balducci L: Estimated Blood Loss in Group O as Compared to Non-group O Radical Prostatectomy Patients. *Hematology*, 1998;3:257-261.
117. Altman DG, LYMAN GH: Methodological Challenges in the Evaluation of Prognostic Factors in Breast Cancer. *Breast Cancer Research and Treatment*, 1998; 52: 289-303.
118. LYMAN GH, Kuderer NM, Balducci L: Economic Impact of Granulopoiesis Stimulating Agents on the Management of Febrile Neutropenia. *Current Opinion in Oncology* 1998;10: 291-298.
119. Jacobs C LYMAN GH Velez-Garcia E et al: A Phase III Randomized Study Comparing Cisplatin and Fluorouracil as Single Agents and in Combination for Advanced Squamous Cell Carcinoma of the Head and Neck. *J Clin Oncol (Classic Papers in Clinic*

1999

120. Schapira DV, Theodossiou C, LYMAN GH: The Effect of NSAIDS on Breast Cancer Prognostic Factors. *Oncol Rep*, 1999;6:433-435.
121. Kamath D, Miliotes G, LYMAN GH, Rapaport D, Cruse CW, Glass F, Fenski N, Messina J, Berman C, Reintgen D: Cutaneous Lymphatic Drainage Patterns in Patients with Grossly Involved Nodal Basins. *Ann Surg Oncol*. 1999;6:345-349.
122. Jacobsen PB, Hann DM, Azzarello LM, Horton J, Balducci L, LYMAN GH: Fatigue in Women Receiving Adjuvant Chemotherapy for Breast Cancer: Characteristics, Course and Correlates. *J Pain and Symptom Management* 1999; 18: 233-242.
123. Bass SS, LYMAN GH, McCann CR, Ku NN, Berman C, Durand K, Bolano M, Cox S, Salud C, Reintgen DS, Cox CE: Lymphatic Mapping and Sentinel Lymph Node Biopsy. *The Breast Journal* 1999; 5: 288-295.
124. LYMAN GH, Kuderer NM, Balducci L: Economic Analyses of the Use of the Colony-Stimulating Factors: An Update in *Current Opinion in Hematology*: 1999;6:145-151.
125. Lazarus HM, Belanger R, Candoni A et al: Intravenous penciclovir for treatment of herpes simplex infections in immunocompromised patients: Results of a multicenter, acyclovir-controlled trial. *Antimicrob Agents Chemother* 1999; 43 (5): 1192-1197.

2000

126. Djulbegovic B, Hozo I, LYMAN GH: Linking Evidence-Based Medicine Therapeutic Summary Measures to Clinical Decision Analysis. *Medscape General Medicine* 2000; January 13

<http://www.medscape.com/Medscape/GeneralMedicine/journal/2000/v02.n01/mgm0113.djul/pnt-mgm0113.djul.html>

127. Pocock SJ, Henerson RA, Clayton T, LYMAN GH, Chamberlain DA: Quality of Life After Coronary Angioplasty or Continued Medical Treatment for Angina: 3-year Follow Up in the Rita-2 Trial. *J Amer College Cardiology*, 2000; 35: 907-914
128. Extermann M, Balducci L, LYMAN GH: What Threshold for Adjuvant Therapy in Older Breast Cancer Patients? *J Clin Oncol* 2000 18: 1709-1717.
<http://www.jco.org/cgi/reprint/18/8/1709.pdf>
129. LYMAN GH: A New Approach to Maintain Planned Dose Chemotherapy on time: A Decision-Making Tool to Improve Patient Care. *European J Cancer*. 2000 36 (suppl): 15-21.
130. Li W, Stall A, Shivers SC, Lin J, Haddad F, Messina J, Glass LF, LYMAN GH, Reintgen DS: Clinical Relevance of Molecular Staging For Melanoma: Comparison of RT-PCR and Immunohistochemistry Staining in Sentinel Lymph Nodes of Patients With Melanoma. *Ann Surgery* 2000; 231: 795-803.
131. Stein KD, Jacobsen PB, Hann DM, Greenberg H, LYMAN GH: Impact of Hot Flashes on Quality of Life Among Postmenopausal Women Being Treated for Breast Cancer. *J Pain Symptom Management* 2000; 19: 436-445.
132. Djulbegovic B, Lacevic M, Cantor A, Fields K, Bennett CL, Kuderer NM and LYMAN GH: The uncertainty principle and industry-sponsored research. *The Lancet* 2000; 356: 635-638.
133. Djulbegovic B, LYMAN GH: Evidentiary Challenges to Evidence-Based Medicine. *J Eval Clin Pract* 2000; 6: 99-109.
134. Balducci L, Hardy CL, LYMAN GH: Hemopoietic reserve in the older cancer patient: clinical and economic considerations. *Cancer Control* 2000 7: 539-547.
135. Broeckel JA, Jacobsen PB, Balducci L, Horton J, LYMAN GH: Quality of Life after adjuvant chemotherapy for breast cancer. *Breast Cancer Research and Treatment* 2000; 62: 141-150.
136. Cox CE, Bass SS, McCann CR, Ku NN, Berman C, Dur K, Boland M, Wang J, Peltz E, Cox S, Salud C, Reintgen DS, LYMAN GH: Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients with Cancer. *Ann Rev Med*, 2000; 51: 525-542.
137. LYMAN GH: A Predictive Model for Neutropenia Associated with Cancer Chemotherapy. *Pharmacotherapy* 2000; 20: 104S-111S.

2001

138. Bass SS, Cox CE, Salud CJ, LYMAN GH, McCann C, Dupont E, Berman C, Reintgen DS: The effects of postinjection massage on the sensitivity of lymphatic mapping in breast cancer. *J. Am. Coll. Surg.* 2001; 192: 9-16.
139. Balducci L, Hardy CL, LYMAN GH: Hematopoietic Growth Factors in the Older Cancer Patient. *Curr Opin Hematology* 2001 8: 170-187.
140. LYMAN GH, Balducci L, Agboola Y: Use of hematopoietic growth factors in the older cancer patient. *Oncology Spectrums*, 2001 2: 414-421.
141. LYMAN GH: Economic Analysis of Randomized Controlled Trials. *Curr Oncol Rep* 2001 Sep;3(5):396-403
142. Balch CM, Soong S-J, Gershenwald J, Thompson JF, Reintgen D, Cascinelli N, Urist M, McMasters K, Ross MI, Kirkwood JM, Atkins MB, Thompson JA, Coit DG, Byrd D, Desmond R, Zhang K, Liu P-Y, LYMAN GH, Moribito A: Prognostic Factors Analysis of 17, 600 Melanoma Patients: Validation of the New AJCC Melanoma Staging System. *J Clin Oncol* 2001 2001; 19: 3622-3634.
143. Djulbegovic B, Adams JR, LYMAN GH, Lacey M, Hozo I, Greenwich M, Bennett CL: Evaluation and appraisal of randomized controlled trials in myeloma. *Annals of Oncology* 2001; 12: 1611-1617.

2002

144. LYMAN GH, Kuderer NM, Djulbegovic B. Prophylactic Granulocyte Colony-Stimulating Factor in Patients Receiving Dose Intensive Cancer Chemotherapy: A Meta-Analysis. *American Journal of Medicine* 2002; 112: 406-411.
145. LYMAN GH, Kuderer NM, Balducci L: Cost-Benefit Analysis of G-CSF in the Management of Elderly Cancer Patients. *Curr Opinion Hematology* 2002; 9: 207-214.
146. Ganguly R, LYMAN G, Lenox B: Hepatitis B Virus Vaccine: Cost effects and insurance coverage. *Am Clin Lab* 2002; 21: 44-46.
147. LYMAN GH, Kuderer NM: Filgrastim in Patients with Neutropenia: Potential Effects on Quality of Life. *Drugs* 2002; 62 Suppl 1: 65-78.
148. Adams JR, LYMAN GH, Djulbegovic B, Feinglass J, Bennett CL: Granulocyte colony stimulating factor as prophylaxis of febrile neutropenia in small cell lung cancer: Review of findings from 13 studies of cost-effectiveness, evidence-based guidelines, patterns of care and surveys of ASCO members. *Exp Opin Pharmacotherapy* 2002; 3: 1273-1281.
149. Balch CM, Soong S-J, Gershenwald J, Thompson JF, Reintgen D, Cascinelli N, Urist M, McMasters K, Ross MI, Kirkwood JM, Atkins MB, Thompson JA, Coit DG, Byrd D, Desmond R, Zhang K, Liu P-Y, LYMAN GH, Moribito A: Prognostic Factors Analysis of

17, 600 Melanoma Patients: Validation of the New AJCC Melanoma Staging System. *Classic Papers and Current Comments* 2002; 7: 406-418.

2003

150. Clark O, LYMAN G, Castro AA, Clark LGO, Djulbegovic B. Colony stimulating factors for the treatment of chemotherapy induced febrile neutropenia. *Cochrane Database Systematic Review*. 2003 3: CD003039.
151. Horan JT, Liesveld JL, Fernandez ID, LYMAN GH, Phillips GL, Lerner NB, Fisher SG: Survival after HLA-Identical Allogeneic Peripheral Blood Stem Cell and Bone Marrow Transplantation for Hematologic Malignancies: a Meta-analysis of Randomized Controlled Trials. *Bone Marrow Transplantation* 2003; 32: 293-298.
152. LYMAN GH, Morrison VA, Dale DC, Crawford J, Delgado DJ, Fridman M. Risk of Febrile Neutropenia Among Patients with Intermediate-grade Non-Hodgkin's Lymphoma Receiving CHOP Chemotherapy. *Leukemia and Lymphoma*. 2003; 44: 2069-2076.
153. Dale D, Crawford J, LYMAN GH: Myelotoxicity and Dose Intensity of Chemotherapy: Reporting Practices from Randomized Clinical Trials. *J National Comprehensive Cancer Network* 2003; 1: 440-454.
154. Haithcox S, Ramnes C, Lee H, Lu J, LYMAN G: The Burden of Frequent Injections on Patients in an Observational Study. *BioMed Central Nursing* 2003 2: 1-15.
155. LYMAN GH, Kuderer NM: Cost Effectiveness of Myeloid Growth Factors in Cancer Chemotherapy. *Current Hematology Reports* 2003; 2: 471-479.
156. Paridaens R, LYMAN GH, Leonard R, Crawford J, Bosly A, Constenla M, Jackisch C, Pettengell R, Szucs: Delivering optimal adjuvant chemotherapy in primary breast cancer: the role of rHuG-CSF. *Eur J Cancer* 2003; 1 (suppl 9): 1-12.
157. LYMAN GH, Delgado D: Risk and Timing of Hospitalization for Febrile Neutropenia in Patients Receiving CHOP, CHOP-R, or CNOP Chemotherapy for Intermediate-grade Non-Hodgkin's Lymphoma. *Cancer* 2003; 98: 2402-2409.
158. LYMAN GH, Kuderer N, Agboola O, Balducci L: Evidence-Based Use of the Colony-Stimulating Factors in Elderly Cancer Patients. *Cancer Control* 2003; 10: 487-499.
159. LYMAN GH, Kuderer NM: Epidemiology of Febrile Neutropenia. *Supp Cancer Ther* 2003; 1: 23-35.
160. LYMAN GH, Dale D, Crawford J: Incidence, Practice Patterns, and Predictors of Low Dose Intensity in Adjuvant Breast Cancer Chemotherapy: Results of a Nationwide Study of Community Practices. *J Clin Oncol* 2003; 21: 4524-4531.

2004

161. Adams JR, Elting LS, LYMAN GH, George JN, Lembersky BC, Armitage JO, Demetri G, Bennett CL: Use of erythropoietin for cancer patients: Assessments of oncologists' practice patterns in the USA and other countries. *Am J Med* 2004; 116: 28-34.
162. LYMAN GH Green SJ, Ravdin PM, Geyer CE, Russell CA, Balcerzak SP, Budd GT, Martino S: A Southwest Oncology Group Randomized Phase II Study of Doxorubicin and Paclitaxel as Frontline Chemotherapy for Women with Metastatic Breast Cancer. *Breast Cancer Research and Treatment* 2004; 85: 143-150.
163. Crawford J, Dale D, LYMAN GH: Chemotherapy-Induced Neutropenia: Risks, Consequences, and New Directions for Its Management. *Cancer* 2004; 100: 228-237.
164. Cosler L, Calhoun E, Agboola O, LYMAN GH: Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy. *Pharmacotherapy* 2004; 24: 488-494.
165. LYMAN GH, Kuderer NM: The Economics of the Colony-Stimulating Factors for the Prevention and Treatment of Febrile Neutropenia. *Critical Reviews of Oncology and Hematology* 2004; 50: 129-146.
166. Hesketh PJ, Batchelor D, Golant M, LYMAN GH, Rhodes N, Yardley D: Chemotherapy-induced Alopecia: Psychosocial Impact and Therapeutic Approaches. *Supp Care Cancer* 2004 12: 543-549.
167. Dubois RW, Pinto LA, Bernal M, Badamgarav E Lyman GH: Benefits of Using GM-CSF Versus Placebo or G-CSF in Reducing Chemotherapy-Induced Complications: A Systematic Review of the Literature. *Supp Cancer Ther* 2004; 2: 34-41.
168. LYMAN GH, Dale D, Friedberg J, Crawford J, Fisher RI: Incidence and Predictors of Low Chemotherapy Dose Intensity in Aggressive Non-Hodgkin's Lymphoma: A Nationwide Study. *J Clin Oncol* 2004: 4302-4311.
169. Komrokji RS, LYMAN GH: The Colony-Stimulating Factors: Use to Prevent and Treat Neutropenia and Its Complications. *Expert Opinion in Biological Therapy* 2004; 4: 1897-1910.

2005

170. Cosler LE, Sivasubramaniam V, Agboola O, Crawford J, Dale D, LYMAN GH: Effect of Outpatient Treatment of Febrile Neutropenia on the Risk Threshold for the Use of CSF in Patients with Cancer Treated with Chemotherapy. *Value in Health*, 2005; 8: 47-52.
171. LYMAN GH, Berndt E, Crown W, Kallich J, Erder H, Finkelstein S: The Economic Burden of Anemia in Cancer Patients Receiving Chemotherapy. *Value in Health* 2005; 8: 149-156.

172. Berndt E, Crown W, Kallich J, Long S, Song X, and Lyman GH. The Impact of Anaemia and its Treatment on Employee Disability and Medical Costs. *Pharmacoeconomics* 2005; 23: 183-192.
173. National Comprehensive Cancer Network: Myeloid Growth Factors in Cancer Treatment Clinical Practice Guidelines in Oncology v. 1.2005: 1-23.
174. Balducci L, Hardy CL, LYMAN GH: Hemopoiesis and aging. *Cancer Treatment and Research* 2005; 124: 109-134.
175. Hornberger, J, Cosler LE, LYMAN GH: Economic Analysis of Targeting Chemotherapy Using a 21-Gene RT-PCR Assay in Lymph-Node–Negative, Estrogen-Receptor–Positive, Early-Stage Breast Cancer. *Am J Managed Care* 2005; 11: 313-324.
176. LYMAN GH, Kuderer NM: The Strengths and Limitations Of Meta-Analyses Based on Aggregate Patient Data. *BMC Medical Research Methodology* 2005; 5: 14: 1-7.
177. LYMAN GH, Kuderer NM: A Primer in Prognostic and Predictive Models: Development and Validation of Neutropenia Risk Models. *Supp Cancer Therapy* 2005; 2: 168-175.
178. Hozo I, Djulbegovic B, Clark O, LYMAN GH: Use of re-randomized data in meta-analysis. *BMC Medical Research Methodology* 2005; 5:17: 1-10.
179. Griggs JJ, Sorbero MES. LYMAN GH: Undertreatment of Obese Women Receiving Breast Cancer Chemotherapy. *Arch Int Med* 2005; 165: 1267-1273.
180. Clark OAC, LYMAN GH, Castro AA, Clark LGO, Djulbegovic B: Colony stimulating factors for chemotherapy induced febrile neutropenia: A meta-analysis of randomized controlled trials. *J Clin Oncol* 2005; 23: 4198-4214.
181. Crawford J, Althaus B, Armitage J, Blayney DW, Cataland S, Dale DC, Demetri GD, Foran J, Heaney ML, Htoy S, Kloth DD, LYMAN GH, Michaud L, Motl S, Vadham-Raj S, Wong MK: Myeloid Growth Factors. *J Natl Compr Canc Netw* 2005; 3: 540-555.
182. LYMAN GH, Lyman CH, Agboola, O: Risk Models for Predicting Chemotherapy-Induced Neutropenia, *The Oncologist* 2005; 10: 427-437.
183. LYMAN GH: Guidelines of the National Comprehensive Cancer Network on the Use of Myeloid Growth Factors with Cancer Chemotherapy: A Review of the Evidence. *J Natl Compr Canc Netw* 2005; 3: 557-571.
184. LYMAN GH, Giuliano AE, Somerfield MR et al: American Society of Clinical Oncology Guideline Recommendations for Sentinel Node Biopsy in Early-Stage Breast Cancer. *J Clin Oncol* 2005; 23: 7703-7720.

185. Basu SK, Fernandez ID, Fisher SG, Asselin B, LYMAN GH: Length of Stay and Mortality Associated with Febrile Neutropenia Among Children With Cancer. *J Clin Oncol* 2005; 23: 7958-7966.
186. LYMAN GH, Djulbegovic B: The Challenge of Systematic Reviews in Cancer Screening, Diagnostic and Staging Studies. *Cancer Treatment Reviews* 2005; 31: 628-639.
187. Khorana AA, Francis CW, Culakova E, LYMAN GH: Risk Factors for Chemotherapy-Associated Venous Thromboembolism in a Prospective Observational Study. *Cancer* 2005; 104:2822-2829.
188. LYMAN GH: Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action. *Expert Opinion in Biological Therapy*. 2005; 5: 1635-1646.
189. Kuthiala SS, LYMAN GH, Ballester OF: Randomized clinical trials for hematopoietic stem cell transplantation: lessons to be learned from the European experience. *Bone Marrow Transplantation*. 2006; 37: 219-221.
- 2006**
190. Kim T, Guliano A and LYMAN GH: Lymphatic mapping and Sentinel Node Biopsy in Early-Stage Breast Cancer: A Meta-analysis. *Cancer* 2006; 106: 4-16.
191. LYMAN GH, Glaspy J: Erythropoietic Therapy in Patients With Chemotherapy-induced Anemia: At What Hemoglobin Level Should Treatment Be Initiated? *Cancer* 2006; 106: 223-233.
192. Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, LYMAN GH: Thromboembolism in Hospitalized Neutropenic Cancer Patients. *J Clin Oncol* 2006; 24: 484-490.
193. Chang SY, Long SR, Kutikova L, Bowman L, Crown WH, LYMAN GH: Burden of Pancreatic Cancer and Disease Progression: Economic Analysis in the US. *ONCOLOGY* 2006; 70: 71-80.
194. Kuderer NM, Dale D, Crawford J, Cosler L, LYMAN GH. The Morbidity, Mortality and Cost of Febrile Neutropenia in Cancer Patients. *CANCER* 2006; 106: 2258-2266.
195. Smith TJ, Khatcheressian J, LYMAN GH et al: 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline. *J. Clin Oncol* 2006; 24: 3187-3205.
196. Komrokji R, Khorana A, Francis C, LYMAN GH: Venous Thromboembolism in Patients with Diffuse Large B Cell Lymphoma. *Leukemia and Lymphoma* 2006; 47: 1029-1033.

197. Wittman B, Horan J, LYMAN GH: Prophylactic Colony-Stimulating Factors in Children Receiving Myelosuppressive Chemotherapy: A Meta-Analysis of Randomized Controlled Trials. *Cancer Treat Rev* 2006; 32: 289-303.
198. Shayne M, Crawford, J, Dale DC, Culakova E, Lyman GH, Predictors of Reduced Dose Intensity in Patients with Early-Stage Breast Cancer Receiving Adjuvant Chemotherapy, *Breast Cancer Research and Treatment* 2006; 100: 255-262.
199. Aapro MS,¹ Cameron DA,² Pettengell R,³ Bohlius J,⁴ Crawford J,⁵ Ellis M,⁶ Kearney N,⁷ LYMAN GH,⁸ Tjan-Heijnen VC,⁹ Walewski J,¹⁰ Weber DC,¹¹ Zielinski C;¹² European Organisation for Research and Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines Taskforce EORTC Guidelines for the use of Granulocyte Colony-Stimulating Factor in Adult Patients with Chemotherapy-Induced Febrile Neutropenia, *Eur J Cancer*, 2006; 42: 2433-2453.
200. Djulbegovic B, LYMAN GH: Screening mammography at 40-49 years: regret or no regret? *The Lancet* 2006: 2035-2037.
201. Crawford J, Althaus B, Armitage J, Blayney DW, Cataland S, Dale DC, Demetri GD, Foran J, Heaney ML, Htoy S, Kloth DD, LYMAN GH, Michaud L, Motl S, Vadham-Raj S, Wong MK: Myeloid Growth Factors.2006.
http://www.nccn.org/professionals/physician_gls/PDF/myeloid_growth.pdf
202. LYMAN GH, Kuderer NM: Gene Expression Profile Assays as Predictors of Recurrence Free Survival in Early Stage Breast Cancer: A Meta-Analysis. *Clin Breast Cancer* 2006; 7: 372-379.
- 2007**
203. Griggs JJ, Culakova E, Sorbero MES, van Ryn M, Poniewierski MS, Wolff DA, Crawford J, Dale DC, LYMAN GH: The Effect of Patient Socioeconomic Status and Body Mass Index on the Quality of Breast Cancer Adjuvant Chemotherapy, *J Clin Oncol* 2007; 25: 277-284.
204. LYMAN GH, Kleiner JM. Summary and Comparison of Myeloid Growth Factor Guidelines in Patients Receiving Cancer Chemotherapy. *J Natl Compr Cancer Netw* 2007; 5: 217-228.
205. LYMAN GH, Cosler LE, Kuderer NM, Hornberger J: Impact of a 21-gene RT-PCR Assay on Treatment Decisions in Early-Stage Breast Cancer: an Economic Analysis Based on Prognostic and Predictive Validation Studies. *Cancer* 2007; 109: 1011-1018.
206. Tang P, Hajdu SI. LYMAN GH: Ductal carcinoma in situ: a review of recent advances. *Curr Opin Obstet Gynecol* 2007; 19: 63-67.
207. Khorana AA, Francis CW, Culakova E, Kuderer NM, LYMAN GH: Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy, *J Thromb Hem* 2007; 5: 632-634.

208. Crawford J, Althaus B, Armitage J, Blayney DW, Cataland S, Dale DC, Demetri GD, Foran J, Heaney ML, Htoy S, Kloth DD, LYMAN GH, Michaud L, Motl S, Vadham-Raj S, Wong MK: Myeloid Growth Factors. *J Natl Comp Cancer Netw* 2007; 5: 188-202.
209. Blumberg N, Zhao H, Wang H, Messing S, Heal JM, LYMAN GH: The Intention to Treat Principle in Clinical Trials and Meta-Analyses of Leukoreduced Blood Transfusions in Surgical Patients. *Transfusion* 2007; 47: 573-581.
210. Cosler LE, Eldar-Lissai A, Culakova E, Kuderer NM, Dale D, Crawford J, LYMAN GH: Therapeutic use of filgrastim for established neutropenia: pharmacoeconomic model predicts overall hospital cost reduction. *Pharmacoeconomics* 2007; 25: 343-351.
211. Griggs JJ, Culakova E, Sorbero MES, Poniewierski MS, Wolff DA, Crawford J, Dale DC, LYMAN GH: Social and Racial Differences in Selection of Breast Cancer Adjuvant Chemotherapy Regimen. *J Clin Oncol* 2007; 25: 2522-2527.
212. LYMAN GH, Shayne M: Granulocyte colony stimulating agents: the right indication, *Current Opinion in Oncology*: 2007; 19: 299-307.
213. Kuderer NM, Dale DC, Crawford J, Lyman GH: Impact of Primary Prophylaxis with Granulocyte Colony-Stimulating Factor on Febrile Neutropenia and Mortality in Adult Cancer Patients Receiving Chemotherapy: A Systematic Review and Meta-Analysis. *J Clin Oncol* 2007; 21: 3158-3167.
214. Eldar-Lissai A, Cosler LE, Culakova E, Lyman GH: Economic Analysis of Prophylactic Pegfilgrastim in Adult Cancer Patients Receiving Chemotherapy. *Value in Health* 2007 (epub ahead of print July 2007).
215. Kuderer NM, Khorana AA, Lyman GH and Francis CF: A Meta-Analysis and Systematic Review of the Efficacy and Safety of Anticoagulants as Cancer Treatment: Impact on Survival and Bleeding Complications. *Cancer* 2007; 110: 1149-1160.
216. Pinto L, Liu Z, Doan Q, Bernal M, Dubois R, LYMAN G: Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain. A meta-analysis of randomized controlled trials. *Current Medical Research and Opinion* 2007; 23: 2283-2295.
217. Shayne M, Culakova E, Poniewierski, MS, Wolff D, Dale DC, Crawford J, LYMAN GH: Dose Intensity and Hematologic Toxicity in Older Cancer Patients Receiving Systemic Chemotherapy, *Cancer* 2007; 110: 1611-1620.
218. Khorana AA, Francis CF, Culakova E, Kuderer NM, LYMAN GH: Frequency, Risk Factors and Trends for Venous Thromboembolism Among Hospitalized Cancer Patients. *Cancer* 2007 (epub Oct 4th 2007 ahead of print).

219. Huston A, LYMAN GH: Agents under investigation for the treatment of neutropenia. Expert Opinion on Investigation Drugs 2007 (in press).
220. LYMAN GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahnanzeb M, Kakkar A, Kuderer NM, Levine M, Liebman H, Mendelson D, Raskob G, Somerfield M, Thodiyil P, Trent D, Francis CW: American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis in Patients with Cancer. *J Clin Oncol* 2007 (in press).
221. Crawford J, Dale DC, Kuderer NM, Culakova E, Poniewierski MS, Wolff D, LYMAN GH: Risk and Timing of Neutropenic Events in Adult Cancer Patients Receiving Chemotherapy: The Results of a Prospective Nationwide Study of Oncology Practice. *J Natl Comp Canc Netw* 2007 (in press).

Invited Publications

1972

222. LYMAN GH: Commencement Address to the Class of 1972, State University of New York at Buffalo School of Medicine, Challenges to Faculty, Graduates, *The Buffalo Physician*, 1972;6:16-19.

1979

223. LYMAN GH, et al: Combination Chemotherapy and Radiation Therapy of Undifferentiated Small Cell Bronchogenic Carcinoma. *Int Med Digest*, 1979; 14-15.

1986

224. LYMAN GH, Lyman CG, Johnson W: Erhohte Leukamieraten in Gebieten mit radioaktiv-Kontaminiertem Grundwasser, *JAMA Deutsche Ausgabe*, 1986;5:20:334-340
225. LYMAN GH, Lyman CG, Johnson W: Leukemia I Kontaminacija Podzemnih Voda Radijumon, *JAMA Jugoslavensko Izdanje*, 1986;brl:51-55.
226. LYMAN GH: Risk of Lung Cancer Associated with Indoor Radon, *Air Quality Communique*, 1986;3:3-6.

1987

227. LYMAN GH: Risk-Reduction and Health Promotion for Older People: The Cost-Effectiveness of Breast Cancer Screening in Preventive Health Care for the Elderly: Hearing before the Subcommittee on Health, Committee on Finance, *US Senate*, US Government Printing Office, Washington DC, 1987;100-451:116-144.
228. LYMAN GH: Human Health and Exposure to Radon: Hearing Before the Subcommittee on Health and the Environment of the Committee on Energy and Commerce, *US House of Representatives*, US Government Printing Office, Washington, DC, 1987;2837:88-96.

229. LYMAN GH: Health Risk Associated with Indoor Radon, *ENFO*, 1987;3:1-4.

1992

230. Schapira D, Kumar N, LYMAN GH, Cavanagh D, Roberts W, LaPolla J: Upper Body Fat Distribution and Endometrial Cancer Risk. *JAMA South America* 1992;266:82-86.

1994

231. Crawford J, Ozer H, Stoller R, Johnson D, LYMAN GH, Tabbana I, Kris M, Grous J, Picozzi V, Rausch G, Smith R, Gradisher W, Yahanda A, Vincent M, Stewart M, Glaspy J: Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer. *Clinical Infectious Diseases*, 1994;18 (suppl 2): 5189-5196.

1998

232. LYMAN GH, Lyman SL, Kuderer NM, Balducci L, Reintgen D, Cox C: Menopausal Status and Breast Cancer Survival Following Recurrence. *Mature Medicine: Canada* 1998;1: 29-31.

2000

233. Adams VR, LYMAN GH: Interactive Discussion on Chemotherapy-Related Adverse Events. *Pharmacotherapy* 2000; 20: 121S-125S.

234. Djulbegovic B, Cantor A, LYMAN GH, Ruckdeschel: Understanding Treatment Benefits and Harms, *Evidence-Based Oncology* 2000; 1: 66-68.

235. Balducci L, LYMAN GH: Farmacoeconomia. *Ematologia Geriatrica* 2000: 1: 49-65.

236. Djulbegovic B, Lyman G, Ruckdeschel JC: Introduction to Survival Analysis. *Evidence-Based Oncology*, 2000; 1: 37.

237. Djulbegovic B, Lyman G, Ruckdeschel JC: Introduction to benefits and risks. *Evidence-Based Oncology*, 2000; 1: 65.

238. Djulbegovic B, Lyman G, Ruckdeschel JC: Continuation. *Evidence-Based Oncology*, 2000; 1: 101.

239. Djulbegovic B, Lyman G, Ruckdeschel JC: Why Evidence-Based Oncology. *Evidence-Based Oncology*, 2000; 1: 2-5.

240. Blaine GM, LYMAN GH: Is Immunochemistry a reliable and prognostically useful tool in the detection of occult axillary lymph nodes in breast cancer? (commentary), *Evidence-based Oncology* 2000; 1: 48-49.

2001

241. LYMAN GH, Djulbegovic B: Understanding Economic Analyses: Evidence-Based Oncology 2001; 2: 2-5.

242. LYMAN GH, Eisenberg PD, Canellos GP, Browman GP: Evidence-Based Oncology Meets Clinical Experience: Opportunities and Challenges. ASCO Educational Book 2001; 37th Annual Meeting: 262-271.
243. Balducci L, Hardy CL, LYMAN GH: Age and Risk of Chemotherapy-Induced Neutropenia. *Neutropenia in Oncology* 2001; 1: 7-11.
244. LYMAN GH, Lyman C, Agboola Y: Risk Models for the Prediction of Chemotherapy-Induced Neutropenia. *Neutropenia in Oncology* 2001;1: 2-7.
245. LYMAN GH, Djulbegovic B: Understanding economic analyses. *Evidence Based Oncology* 2001; 2: 2-5.

2002

246. LYMAN GH, Kuderer NM: American Society of Clinical Oncology 2002 Overview on Neutropenia. *Neutropenia in Oncology*. 2002; 2: 2-7.
247. Sivasubramaniam V, LYMAN GH: Compared to tamoxifen, letrozole increases tumor response in post-menopausal women with advanced breast cancer, *Evidence-Based Oncology* 2002; 3: 29-30.

2003

248. Djulbegovic B, Coleman R, Stahel R, Singh D, LYMAN G: Evidence-Based Oncology. *Cancer Treatment Reviews* 2003; 29: 45-50.
249. LYMAN GH: The Challenge of Systematic Reviews in Screening, Diagnostic and Staging Studies. ASCO 2003 Educational Book; 39th Annual Meeting: 2003; 759-770.
250. Shunyakov L, LYMAN GH: A Young Patient with Recently Diagnosed Breast Cancer Receiving Neoadjuvant Dose Dense Chemotherapy with Pegfilgrastim Support. *Case Studies in Supportive Care* 2003 2; 1-7.
251. LYMAN GH: Balancing the Benefit and Cost of Colony-Stimulating Factors: A Current Perspective. In *Advances in the Management of Chemotherapy-Induced Neutropenia* (H Ozer, ed) *Seminars in Oncology* 2003 30 (4 Suppl 13): 10-17.
252. LYMAN GH: Neutropenia Risk Models in Oncology. Introduction (GH Lyman, ed) *Oncology* 2003; 17: 5-7.
253. LYMAN GH: Risk Assessment in Oncology Clinical Practice: From Risk Factors to Risk Models. In *Risk Models in Oncology* (GH Lyman, ed) *Oncology* 2003; 17: 8-13.

2004

254. Cosler LE, Eldar-Lissai A, LYMAN GH: The Role of Colony-Stimulating Factors in the Management of Febrile Neutropenia. Hospital Pharmacy Europe 2004 September/October; 65-66.

2005

255. LYMAN GH, Kuderer NM: Moving Beyond Febrile Neutropenia. Supp Cancer Ther 2005; 2: 95-97.

256. LYMAN GH: Time is Money for Both the Healthy and the Sick. Medical Care 2005; 43: 637-639.

2006

257. LYMAN GH, Berndt ER, Kallich J, Erder MH, Crown W, Long SR, Lee H, Song X, Finkelstein SN: The Economic Burden of Anemia in Cancer Patients Receiving Chemotherapy. Focus on Anaemia in Cancer 2006 (in press).

258. LYMAN GH, Glaspy J: Examining the Benefits of Early Erythropoietic Intervention in Patients with Chemotherapy-Induced Anemia. Am J Oncol Rev 2006; 5: 236-241.

259. LYMAN GH: Benefits of Early Intervention with Erythropoiesis-Stimulating Proteins in Chemotherapy-Induced Anemia, ONCOLOGY 2006; 20: 16-20.

260. LYMAN GH, Glaspy J: Management of Cancer-Induced Anemia (editors), ONCOLOGY 2006; 20: 1-44.

261. LYMAN GH: Chemotherapy Dose Intensity and Quality Cancer Care in ONCOLOGY (supplement 9): Advances in the Management of Chemotherapy-Induced Neutropenia (J Crawford, ed) 2006; 20: 9: 16-25.

262. LYMAN GH: Introduction to Chemotherapy-Induced Neutropenia. Clinical Cornerstones (Supplement on Neutropenia, edited by LYMAN GH), 2006; 8: S4.

263. LYMAN GH: Risks and Consequences of Chemotherapy-Induced Neutropenia. Clinical Cornerstones (Supplement on Neutropenia, edited by LYMAN GH), 2006; 8: S12-S18.

2007

264. LYMAN GH: Economics of Cancer Care. J Onc Pract 2007; 3: 113-114.

Editorials/Commentary/Letters

1979

265. Weiner RS, Vogel CL, LYMAN GH: Breast Cancer Treatment Update, *Univ Florida*, 1979.

1980

266. LYMAN GH, Williams CC, Preston D: Lithium Carbonate During Chemotherapy. *New England Journal Med.*, 1980;302:1365.

1983

267. LYMAN GH: Space Wars, *St. Petersburg Times*, Sunday, April 17, 1983.

268. LYMAN GH: Does H-Bomb Parts Plant Pose Hazard? *St. Petersburg Times*, Sunday, June 26, 1983

1984

269. LYMAN GH: Where Would Everybody Go? Nuclear Civil Defense, *St. Petersburg Times*, Sunday, March 4, 1984.

1986

270. LYMAN GH, Lyman C, Johnson W: Leukemia and Radium Groundwater Contamination. *J Am Med Assoc*, 1986;255:902-903.

271. LYMAN GH, Lyman CG: Leukemia and Groundwater Contamination. *J Am Med Assoc*. 1986;256:2676-2677.

1987

272. LYMAN GH: Groundwater Radium and Indoor Radon as Causes of Cancer. *Innovations in Oncology*, 1987;3:13-14.

1988

273. LYMAN GH: The Ethics of Clinical Cancer Trials. *Today's Tomorrows*, 1988:3-17.

274. LYMAN GH: Environmental Risks For Lung Cancer. *Proceedings, National Cancer Advisory Board*, Miami, FL, February 11, 1988.

1993

275. LYMAN GH, Lyman CG, Sanderson RA, Balducci L: Decision Analysis of Hematopoietic Growth Factor Use, *J Natl Cancer Inst.*, 1993;85:1252-1253.

1994

276. Balducci L, LYMAN GH: Cost-Effectiveness of Hematopoietic Growth Factors. *Advances in Oncology*, 1994;10:10.

2000

277. Djulbegovic B, Lyman G, Ruckdeschel JC: Welcome and Introduction. *Evidence-Based Oncology*, 2000; 1: 1.

278. Djulbegovic B, Hozo I, LYMAN GH: Integration of Population-Derived Therapeutic Measures Within a Decision Analytic Framework to Tailor Treatment Toward Individual Patients. *Ann Int Med* 2000 132: 93-94.

279. Djulbegovic B, Bennett CL, Adams JR, LYMAN GH: Industry-Sponsored Research. Lancet 2000; 2193-2194

2001

280. Balducci L, LYMAN GH: Patients Aged > 70 Are at High Risk for Neutropenic Infection and Should Receive Hemopoietic Growth Factors When Treated With Moderately Toxic Chemotherapy. J Clin Oncol 2001; 19: 1583-1585.

281. LYMAN GH, Lininger LL: NEUTROPENIA: Clinical Prediction Models for Febrile Neutropenia (FN) and Relative Dose Intensity (RDI) in Patients Receiving Adjuvant Breast Cancer Chemotherapy. Presentations in Focus: Chemotherapy Support: New Advances in the Management of Anemia and Neutropenia, 2001: 13

282. LYMAN GH, Kuderer, NM: Risk Factors for Neutropenia in Advances in Chemotherapy and Supportive Care, Albert Einstein College of Medicine CME, 2001

2002

283. LYMAN GH, Kuderer NM: The Impact of Anemia on Quality of Life in Pharmacoeconomics of Cancer Care, Albert Einstein College of Medicine CME, 2002

284. LYMAN GH: Oncology Case Series: Diffuse Large B-Cell Lymphoma-Elderly Patient, Network for Oncology Communication and Research, 2002: F-11

285. Whitney JF, LYMAN GH: Exercise Prescription. Ann Int Med 2002; 136: 564.

286. LYMAN GH, Kuderer NM, Djulbegovic B: Overlooking Patient Outcomes in a Meta-Analysis of Trials of Granulocyte Colony-Stimulating Factor. Am J Med 2002 113: 766-768.

2003

287. LYMAN GH, Lyman SL: Predicting Hematologic Toxicity: Risk Models and Their Utility. Cancer Investigation 2003; 21: 15-16.

2004

288. LYMAN GH, Culakova E, Griggs J: Use of Antibiotics and Risk of Cancer. J Am Med Assoc 2004; 291: 2699-2700.

289. LYMAN GH: Breast Cancer Update: Conversations with Oncology Research Leaders. Bridging the Gap between Research and Patient Care (Neil Love, ed), 2004; 3: 13-18.

290. Lyman GH (editor); ASH 2003 Conference Report; On-Site ASH 2003 Newsletter. 2004; 7: 1-8

291. Lyman GH: Adjuvant Chemotherapy. Patterns of Care in Medical Oncology 2004; 1: 13-22.

292. LYMAN GH, Glaspy J, Berger AM: Comprehensive Management for Optimal Care of Patients with Cancer. CME CD-ROM Program, New York Medical College, 2004.

2005

293. LYMAN GH: Chemotherapy-Induced Neutropenia: Opportunities for Improved Management. Comprehensive Management for Optimal Care of Patients with Cancer. Multimedia CD-ROM program, Continuing Education Alliance, Greenwich, CT.

294. LYMAN GH: Management of Breast Cancer in the Adjuvant and Metastatic Settings in Patterns of Care in Medical Oncology. 2005; 2: 1-52.

295. LYMAN GH: New Paradigm for Growth Factor Support. Reduction of Febrile Neutropenia and Its Complications. Oncology Journal Club, 2005; Duke University, Durham NC

296. Clark O, LYMAN GH, Djulbegovic B: Is the Statistical Difference Clinically Relevant? J Clin Oncol 2005; 23: 8537-8538.

2006

297. LYMAN GH: Withholding Antibiotics from Patients with Febrile Neutropenia. J Clin Oncol 2006; 24: 1221-1222.

298. LYMAN GH: Oncology Case Studies: Non-Hodgkin's Lymphoma: Supporting Platelet Counts to Optimize Chemotherapy Outcomes. CRG Oncology, Tarrytown, NY

299. LYMAN GH: Oncology Practice Update 2006; 1: 1-24.

300. Lyman GH: Book Review: The Global Cost of Cancer, Lancet Oncology 2006; 7: 809-810.

301. LYMAN GH: Clinical Commentary: Thoughts on Emerging Therapies. Managed Care Consultant, American Academy of CME 2006.

302. LYMAN GH, Crawford J, Dale DC, Friese CR: Chemotherapy-Induced Neutropenia Prevention: Implications of New Clinical Data and Guidelines. www.CMEDiscovery.com

303. LYMAN GH: Glaspy J, Cosler LE, Friese CR: Chemotherapy-Induced Anemia: Current Therapeutic Trends. www.CMEDiscover.com

2007

304. LYMAN GH: The Moving Target of Cancer Care Costs, Oncology 2007; 21: 862-866.

305. Griggs JJ, Culaková E, LYMAN GH: The Effect of Patient Socioeconomic Status and Body Mass Index on the Quality of Breast Cancer Adjuvant Chemotherapy, J Clin Oncol 2007; 25: 2332.

306. LYMAN GH: Gene Expression Profile Assays as an Aid in Treatment Decision Making in Early-Stage Breast Cancer. *J Oncol Pract* 2007; 3: 187-188.
307. LYMAN GH: Clinical Practice Guidelines and Beyond. *J Onc Pract* 2007 (in press).
308. LYMAN GH: Obesity: Double Jeopardy. *Breast Diseases: A Year Book Quarterly*. 2007 (in press).
309. LYMAN GH: Advances in *Cancer Investigation*. *Can Invest* 2007 (in press).

Published Abstracts

1975

1. Preisler HD and LYMAN GH: Properties of Compounds Which Induce the Differentiation of Friend Leukemia Cells (FLC) *In Vitro*. *Proc Am Assoc Can Res*, 1975;16:187.
2. Ambrus JL, Bettigole R, Ambrus CM, LYMAN GH et al: Hematologic Consequences of Altered Vascularity and Biochemistry of Neoplastic Tissue, *Internal Journal of Radiation Oncology, Biology and Physics*, 1975.

1976

3. Jordon E, LYMAN GH, Higby DJ, Henderson ES: Apparent Conversion of Lymphocytic to Myelocytic Leukemia. *Proc Am Soc Clin Oncol*, 1976;17:285.
4. Preisler HD, LYMAN GH: Acute Myelocytic Leukemia (AML) Subsequent to Treatment for other Malignancies Therapogenic AML, T-AML. *Proc Amer Soc Hemat*. 1976;136.

1977

5. Plumb M, Simon J, and LYMAN GH: Factors Affecting Morale of Inpatient Staff in a Cancer Treatment Center. *Proc Am Soc Clin Oncol*, 1977;18:329.

1978

6. LYMAN GH, Hartmann RC, Saba HI, Preston D, Knight M: Combination Chemotherapy and Radiation Therapy of Oat Cell Bronchogenic Carcinoma. *Clin Res* 1978;26:36a.
7. Saba HI, LYMAN GH, Dinwoodie WR, Hartmann RC: Efficacy of "Continued" Pulse Regimen of Alkeran and Prednisone in the Treatment of Multiple Myeloma. *Clin Res*. 1978;26:441a.
8. Ambrus JL, Ambrus CL, LYMAN GH, Bettigole RE: Metabolism of Fibrinogen in Cancer Patients. *Proc Am Soc Clin Oncol*, 1978;19:404.

9. LYMAN GH, Williams CC, Preston D: Prospective Randomized Study of the Effect of Lithium Carbonate on the Granulocytopenia and Incidence of Infection Associated with Intensive Chemotherapy and Radiation Therapy for Undifferentiated Small Cell Bronchogenic Carcinoma. *Blood (Supple)*, 1978;52:228.
10. LYMAN GH, Garms P: Effect of Divalent Cations and Combinations of Cryoprotective Agents of Human Erythrocytes. *Clin Res*, 1978;26:765a.

1979

11. Preisler HD, LYMAN GH: Acute Myelogenous Leukemia Subsequent to Therapy for a Different Neoplasm: Clinical Features and Response to Therapy. *Yearbook of Cancer*, Clark RE, Cumley RW, Hickey RC (eds), Yearbook Medical Publishers, Chicago, 1979;264.
12. LYMAN GH, Williams CC: Evaluation of the Extent of Disease in Undifferentiated Small Cell Bronchogenic Carcinoma (USCBC) *Clin Res* 1979;27:389a.
13. Williams CC, LYMAN GH, Dinwoodie WR, Saba HI, Hartmann RC, Preston D: Treatment Results and Toxicity of Lithium Carbonate (L) in the Combined Modality Management of Small Cell Lung Cancer. *Proc am soc Clin Oncol*, 1979;20:428.
14. LYMAN GH, Gilio MJ: Ultrastructural Alterations Associated with Dimethylsulfoxide (DMSO) Induced Friend Erythroleukemia Cell (FLC) Differentiation In Vitro: Cell Surface Analysis. *Proc Am Assoc Can Res*, 1979;20:289.
15. Williams CC, LYMAN GH: Improved Results in the Treatment of Acute Myelogenous Leukemia. *Proceedings Second Annual Cancer Research Seminar*, American Cancer Society, 1979.
16. LYMAN GH, Williams CC, Preston D, Hartmann RC, Saba HI, Goldman L, Shukovsky L, Jensen R: Lithium Carbonate Administration in Patients with Advanced Small Cell Bronchogenic Carcinoma Receiving Combination chemotherapy and Radiotherapy. *Proceedings of Conference on Lithium Effects on Granulopoietic and Immune Function*, 1979.
17. LYMAN GH, Armistead S, Williams CC, Crowder C, Colledge P, Knight M, Johnson D: Bleomycin and Prolonged Infusion Cisdiamminodichloroplatinum (CCDP) in Advanced Squamous Cell Carcinoma of the Head and Neck. *Clin Res*, 1979;27:759a.
18. LYMAN GH, Azar H, Garcia W, Crowder C, Armistead S, Blanco R: Advanced Non-Hodgkin's Lymphoma; Recent Experience with Three Chemotherapy Regimens. *Blood (Supple)*1979;54:196a.

1980

19. Sokol GH, LYMAN GH, Paladine W, Drapkin R, Gordy L, Ruffalo E, Staff A, Solomon D: The Accuracy of Cytology as Compared to Tissue Biopsy in the Diagnosis and Subtyping of Small Cell Carcinoma of the Lung. *Proc Am Soc Clin Oncol*, 1980;21:460.

20. LYMAN GH, Colledge P, Johnson D, Williams CC: Chemotherapy of Advanced Bronchogenic Carcinoma with methotrexate, Adriamycin, Cyclophosphamide, CCNU and Vincristine. *Proc Am Soc Clin Oncol*, 1980;21:460.
21. Cox WI, Spector S, LYMAN GH, Friedman H: Reversal of the Immunosuppressive Effects of Friend Leukemia Virus Transformed Cells by Dimethylsulfoxide (DMSO), *Florida Scientist* (Supple), 1980;43:45.
22. LYMAN GH, Williams CC, Dinwoodie WR, Knight M: The Effect of Chemotherapy Intensity on Lithium Attenuation of Myelosuppression and Infection. *Blood* (Supple), 1980;55:182.
23. LYMAN GH, Colledge P, Johnson D, Williams CC: Advanced Adenocarcinoma of the Lung: Recent Treatment Results with Combination Chemotherapy. *Clin Res*, 1980;28:418a.

1981

24. Cox WI, Spector SC, LYMAN GH, Friedman H: Alteration of the Susceptibility of Friend Erythroleukemia Cells to Natural Cytotoxicity. *Proc Am Soc Microbiology*, 1981.
25. Cox WI, Spector S, LYMAN GH, Friedman H: Acquired Sensitivity of Friend Erthroleukemia Cell Line to Natural Killer Cells. *Proc 4th Annual Cancer Research Seminar*, Tampa, FL;1981.
26. Azar HA, Fernandez S, Bros L, Espinoza CG, Shelly SA, LYMAN GH: Effect of Bleomycin on two Human Squamous Cell Carcinomas Transplanted in nu/nu mice. *Fed Proc 40 (II)*; 1981;818.
27. Drapkin R, Griffiths E, McAloon E, Paladine W, Sokol G, LYMAN GH: Sequential Methotrexate (MTX) and 5-Fluorouracil (5-FU) in Adenocarcinoma of the Colon and Rectum. *Proc Am Soc Clin Oncol*, 1981;22:505.
28. LYMAN GH, Williams CC, Dinwoodie WR, Richman A: Intensive Combination Chemotherapy and Radiotherapy for Small Cell Bronchogenic Carcinoma (SCRC). *Proc Am Soc Clin Oncol*, 1981;22:505.
29. Williams CC, LYMAN GH: Cis-Diamminodichloroplatinum (CDDP) and Bleomycin (B) in Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN). *Proc Am Soc Clin Oncol*, 1981;22:532.
30. Azar HA, Balis JU, Halkias DG, LYMAN GH, Nelson, Richman AV: Human-Tumor Xenografts in NU-NU Mice-Observations on Successful and Unsuccessful Transplants. *Ann Clin Lab Sci* 1981;11:440-441.

31. Sokol GH, Drapkin R, Paladine W, Price L, LYMAN GH, McCarthy S, Chadwick R: the Efficacy of Double Dose Trimethoprim (Tigan) and the Modification of Radiation-Induced Nausea – A Double-Blind Prospective Randomized Study. *Int J Radiation Oncology Biology Physics* 1981;7:1254.
32. LYMAN GH, Williams CC: Serum Lithium Level and the Attenuation of Chemotherapy Myelosuppression. *Proc Am Assoc Cancer Res*, 1981;22:177.
33. LYMAN GH, Williams CC, Dinwoodie WR, Johnson D: Early Death in Patients with Electrocardiographic (EKG) Abnormalities Receiving Lithium Carbonate. *Proc Am Soc Clin Oncol*, 1981;22:423.
34. Breen JF, Maglio S, Saba HI, LYMAN GH: Prophylactic Antibiotics in Hospitalized Granulocytopenic Patients. *Clin Res*, 1981;29:835a.

1982

35. Drapkin RL, Sokol GH, Paladine WJ, Polackwich R, LYMAN GH: The antiemetic Effect and Dose Response of Dexamethasone in Patients Receiving Cis-Platinum. *Proc Am Soc Clin Oncol*, 1982;1:61.
36. Penta JS, Sokol GH, Wall T, Greenberg H, Gilliland CD, LYMAN GH, Jimenez J, Bingham RH: Phase I Studies of Biological Response Modifier (BMR) Agents. *Proc Fifth Annual Cancer Research Seminar*, American Cancer Society, 1982.
37. Bennett JM, Cassileth PA, Begg CB, LYMAN GH, Oken M, Boxdech MJ, Glick JH: For the Eastern Cooperative Oncology Group. The Phase II Trial of Acridinyl Anisidine (m-AMSA) and VP-16-213 in Refractory Acute Myeloid Leukemia in Adults. *Proc Am Soc Clin Oncol*, 1982;231:135.

1983

38. Drapkin R, McAloon E, LYMAN GH: Sequential Methotrexate (MTX) and 5-Fluorouracil in Advanced Measurable Colorectal Cancer. *Proc Am Soc Clin Oncol*, 1983;2:118.
39. Schocken DD, Nobel JC, LYMAN GH, Sbar S, Harrison FE: Left Main Coronary Disease in the Elderly: Sex Differences in Clinical Variables. *Proc American Heart Association*, 1983.
40. Nobel JC, LYMAN GH, Schocken DD: Assessing the Elderly Patient with Left Main Coronary Disease: Predictors of Anatomic Severity. *Clin Research*, 1983.
41. LYMAN GH: The Role of Lithium in Cancer Chemotherapy. *Proc Am Chem Soc*, (Sermacs-35);1983:10.

1984

42. LYMAN GH, Azar HA, Katta T, Colledge P: Histopathologic Classification and Transformation of Non-Hodgkin Lymphoma. *Proc Am Soc Clin Oncol*, 1984;3:248.

1985

43. Dinwoodie WR, Bartolucci A, LYMAN GH: Cisplatin, Bleomycin and Vindesine in Advanced Squamous Cell Carcinoma of the Esophagus. *Proc Am Soc Clin Oncol.*, 1985;4:80.
44. LYMAN GH, Lyman CG, Johnson W: Leukemia Associated with Radium Groundwater Contamination. *Proc Am Assoc Can Res*, 1985;26:206.
45. Williams CC, LYMAN GH, Dinwoodie WR, Tedford KJ, Harley C: The Risk of Leukopenia and Infection Associated with Low Pretreatment and Recovery Lymphocyte counts in Patients Receiving Chemotherapy. *Proc Am Soc Clin Oncol*, 1985;4:259.
46. Raymond MG, LYMAN GH: Treatment of Unrespectable/Recurrent Epidermoid Carcinoma of the Head and Neck with Cisplatin Plus 5-Fluorouracil Infusion. *Proc Am Soc Clin Oncol*; 1985;4:133.
47. LYMAN GH, Gams R, Vogler R, Raney M: A Phase II Multi-Institutional Study of Mitoxantrone in Refractory Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Blastic Chronic Myeloid Leukemia. *Proc Am Soc Clin Oncol*, 1985;4:158.
48. Cintron G, Medina R, Reyes A, LYMAN GH: Dental Procedures in Patients with Recent Uncomplicated Acute Myocardial Infarction. *Proc Annual Session AHA*, 1985.
49. LYMAN GH, Lyman CG: Morphologic, Temporal and Geographic Variation of Leukemia in a Population Based Registry. *Blood (suppl)*. 1985;66:179a.
50. LYMAN GH, Vogler R, Raney M: Aziridinybenzoquinone (AZQ) (NCS#182986) in Acute Myelogenous Leukemia (AML): Results of a Phase II Multi-institutional Study. *Blood*, (supple), 1985;66:204a.
51. Williams CC, Tedford KJ, LYMAN GH, Harley C, Dinwoodie WR: Correlation of Total White Blood Count (WBC) and Differential Counts in Cancer Patients Receiving Combination Chemotherapy. *Exp Hemat (supple)* 1985;16:118-119.

1986

52. McCarley D, Noyes W, Martelo O, LYMAN GH, Vogler W: For the Southeastern Cancer Study Group: High Dose Cytosine Arabinoside (HD-ARA-C) VS HD-ARA-C + VP-16 as Reinduction Therapy for Relapsed and Refractory Acute Myelogenous Leukemia (AML): A Preliminary Report from the Southeastern Cancer Study Group. *Proc Am Soc Clin Oncol*, 1986;5:164.
53. Sokol GH, Greenberg HM, McCarthy S, Sledjeski L, LYMAN GH: Radiation Induced Nausea (RIN): The Comparative Efficacy of Oral Metoclopramide (M) versus Prochlorperazine (P) and Placebo (PL). *Proc Am Soc Clin Oncol*. 1986;5:248.

54. Cullison J, Yangco BG, LYMAN GH: Infectious Complications Associated with Near Drowning (ND), *ICAAC*, 1986.
55. Schocken DD, Novel JC, Worden TC, Krug-Frite J, LYMAN GH: Predicting Left Main Coronary Disease in the Elderly Using a Matched Cohort. *X World Congress of Cardiology*, 1986.
56. Stockwell HG, LYMAN GH, Waltz J: Exposure to Low levels of Ionizing Radiation and Lung Cancer Risk in Florida. *Am J Epi*, 1986;124:500.
57. Wickstrom EL, Wickstrom E, LYMAN GH, Freeman DL: HL-60 Cell Proliferation Inhibited by an Anti-c-myc Pentadecadeoxynucleotide. *Leukemia Society of America, Second Annual Medical Conference*, 1986, Wesley Chapel, FL.
58. Wickstrom EL, Wickstrom E, LYMAN GH, Freeman DL: HL-60 proliferation Inhibited by an Anti-c-myc Pentadecadeoxynucleotide. *American society of Biological Chemists. 77th Annual Meeting*, 1986, Washington, DC.
59. LYMAN GH, Stockwell HG: Cigarette Attributable Risk of Cancer in Women. *Prevent Med.* 1986;15:701-702.

1987

60. Colajori E, Carr BI, Luce JK, LYMAN GH, Einhorn LH, Hande KR, Beck TM, Sridhar K: A Multicenter Clinical Study Comparing Cyclophosphamide, Epirubicin and Vincristine to Cyclophosamide, Doxorubicin and Vincristine in the Treatment of Small Cell Bronchogenic Carcinoma, *Proc Am Assn Cancer Res.*, 1987;28:214.
61. Stockwell HG, LYMAN GH, Peters JT: Variations In Lung Cancer Cell Type Among Women. *Prevent Med.*, 1987;16:280.
62. LYMAN GH: Age Specific Progress Against Cancer., *Proc Am Soc Clin Oncol.*, 1987;6:224.
63. Goldschmid S, Boyce HW, Brown JI, Brady PG, Nord HJ, LYMAN GH: A New Objective Measurement of the Severity of Dysphagia. *Am Soc GI Endoscopy*, 1987.
64. Schapira D, Kumar N, McMillan S, LYMAN GH: The Public's Knowledge of Dietary Recommendations and Food Labeling. *J Cancer Education*, 1987;2:4.

1988

65. Drapkin R, Stanton G, McCreary R, McAloon E, Solomon E, LYMAN GH, Osterly S, Speilberg CD: State Anxiety, Trait Anxiety and Anger Expression in Oncology Patients Receiving Chemotherapy. *Proc Am Soc Clin Oncol.*, 1988;7:270.
66. Jacobs C, LYMAN GH, Velez-Garcia E, Sridhar KS, Schacter L, Dalton T, Roxencweig M: Comparison of Infusion al 5-Fluorouacil (5-FU) and Cisplatin (CDDP) in Combination

and as Single Agents for Recurrent and Metastatic Head and Neck Cancer. *Proc Am Soc Clin Oncol.*, 1988;7:154.

67. Blanchard DK, Serbousek D, LYMAN GH, Kavanagh JJ, Nicoletto JP, Djeu JY: Lysis of Autologous Monocytes by Lymphokine-Activated Killer (LAK) Cells From Cancer Patients. *Proc am Soc Clin Oncol.*, 1988;29:396.
68. Schapira DV, Kumar N, LYMAN GH, Baile W: The Efficacy of Long and Short Term Dietary Interventions. *J Cancer Educ.*, 1988;3:300-301.
69. Schapira D, Kumar N, LYMAN GH, Cox C: Body Fat Distribution and Breast Cancer Risk. *Breast Cancer Res and Treatment*, 1988;12:143.
70. Schapira DV, Kumar N, McMillan S, LYMAN GH: Public Awareness of Food Labeling. *Food and Society*. 1988.
71. Schapira DV, Kumar N, McMillan S, LYMAN GH: The Public Knowledge of Dieting Recommendations and food Labeling. *J Can Educ.*, 1988;2:4.
72. Morris D, LYMAN GH, Muus C: Extra-Medullary Relapse of Acute Myelogenous Leukemia at Phlebotomy and Bone Marrow Biopsy Sites. *Blood*, 1988;72:217a.
73. Djeu JY, Serbousek D, LYMAN GH, Kavanagh JJ, Nicoletto JP, Blanchard DK: Lymphokine-Activated Killer (LAK) Cell Activity Against Autologous Monocytes in Cancer Patients. *Fed Am Soc Exp Biol*, 1988.

1989

74. Morris D, LYMAN GH, Muus C, Lee H: Probable False Positive Melanoma Monoclonal Antibody Scans in Two Patients with Second Primaries. *Proc Am Soc Clin Oncol.* 1989;8:286.
75. Hoffman M, Molpus K, Roberts WS, LYMAN GH, Cavanagh D: Tubovarian Abscess in Postmenopausal Women. *Proc Annual Meeting American College of Obst Gyn.* 1989;6.
76. LYMAN GH, Balducci L, Effenbein GJ, Fields K, Saleh R: Allogenic Bone Marrow Transplantation (BMT) versus Consolidation Chemotherapy (CTX) After Remission Induction in Adults With Acute Myelogenous Leukemia (AML). *Blood (supple)*, 1989;74:362a.
77. Saker A, Moscinski L, Papenhausen P, LYMAN GH: Acute Nonlymphocyte Leukemia (ANLL) With INV(6) and Trisomy 21 Displaying FAB M2 Morphology with Elevated Serum Lysozyme. *Blood (supple)*, 1989;74:368a.
78. Schapira DV, Kumar N, LYMAN GH, Baile W: Health Attitude and Dietary Change. *J Can Educ.*, 1989;4:37.

79. Schapira DV, Kumar N, LYMAN GH, Cox C: Body Fat Distribution and Breast Cancer Risk. *Canc Detec and Prev.*, 1989;14:66.
80. Wickstrom FL, Bucon TA, Gonzolez A, Freeman DL, LYMAN GH, Wickstron E: Human Promyelocytic Leukemia HL60 Cell Proliferation and c-myc Protein Expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc MRNA. *Yearbook of Oncology*, 1989;116-117.

1990

81. Schapira D, Kumar N, LYMAN GH: The Effect of Tamoxifen Therapy on Serum Cholesterol, *Proc Am Soc Clin Oncol*, 1990;9:49.
82. Crawford J, Ozer H, Johnson D and G-CSF Study Group Granulocyte, Colony Stimulating Factor: Prevention of Chemotherapy Induced Febrile Neutropenia in Patients with Small Cell Lung Cancer: A Randomized Double Blind Placebo Controlled Trial. *Proc Am Soc Clin Oncol.*, 1990;9:229.
83. Balducci L, Schonwetter R, Grey J, Tantranond P, Hescoock H, LYMAN GH: Individualized Treatment of the Older Cancer Patient: A Decision Analysis. *Proc American Geriatrics Society*, 1990.
84. Benson K, Balducci L, LYMAN GH, Fields K, Saleh T, Siddiqui G, Elfenbein G: Cost Effectiveness of Leukocyte Depleted Blood Components (LDC). *Proc Am Soc Clin Oncol*, 1990;9:325.
85. Balducci L, Schonwetter R, Hescoock H, Tantranond P, Grey J, LYMAN GH: Decision Analysis in Geriatric Oncology. *Proc Am Soc Clin Oncol*, 1990;9:99.
86. Schapira K, Kumar N, LYMAN GH, Cox C: Effect of Body Fat Distribution on Lymph Node and Estrogen Receptor Status at Diagnosis. *Proc Am Soc Clin Oncol.*, 1990;9:49.
87. Schapira DV, Kumar NB, LYMAN GH, Cox CE: Body Fat Distribution and Breast Cancer Risk. *Obs/Gyn Digest*, 1990.
88. Balducci L, Schonwetter R, Grey J, Tantranond P, Hescoock H, LYMAN GH: Individualized Treatment of the Older Cancer Patient. *Proc Am Geriatric Soc*, 1990.
89. Schapira D, Kumar N, LYMAN GH: Breast Cancer Reduction with Weight Loss. *Breast Cancer Research and Treatment*, 1990.
90. Schapira D, Kumar N, LYMAN GH, Cox C: Effect of Body Fat Distribution and Obesity in Breast Cancer Diagnosis. *Breast Cancer Research and Treatment*, 1990.
91. Balducci L, Benson K, Fields K, Saleh R, Elfenbein G, LYMAN G: Leukocyte Depleting Filters and Transfusions of Blood Components in Adult Acute Leukemia: A Decision Analysis. *Blood (supple)*, 1990;76:394a.

92. Eifenbein G, Fields K, Saleh R, Kalman L, LYMAN GH, Balducci L: High Dose Chemotherapy with Autologous Bone Marrow Rescue as Adjuvant Treatment of Stage 2 Breast Cancer: A Decision Analysis. *Blood (supple)*, 1990;76:536a.
93. Benson K, Noll L, LYMAN GH, Morris D, Schapira D: Loss of B, Then A Antigens with Progression of Myelodysplastic Syndrome (MDS) to Acute Leukemia. *Proc Am Assoc Blood Banks*, 1990;27.
94. Schapira DV, Kumar NB, LYMAN GH: The Effect of Tamoxifen Therapy on Serum Cholesterol. *Proc Am Soc Clin Oncol*, 1990:186.

1991

95. Jacobs C, LYMAN G, Velez-Garcia E, Sridhar K, Cherng N, Roxencweig M: A Phase III Study Comparing Cisplatin and Fluorouracil as Single Agents and in Combination for Advanced Squamous Cell Carcinoma of the Head and Neck: A Final Report. *Proc Am Soc Clin Oncol*. 1991;10:197.
96. Schapira DV, Kumar N, LYMAN GH: Obesity, Body Fat Distribution and Sex Hormones in Breast Cancer Patients. *Proc Am Soc Clin Oncol.*, 1991;10:85.
97. Schapira DV, Kumar N, LYMAN GH, Cavanagh D, Roberts W, LaPolla J: Abdominal Obesity and Endometrial Cancer Risk. *Proc Am Soc Clin Oncol*. 1991;10:85.
98. Schapira DV, Kumar NB, LYMAN GH: The Effect of Tamoxifen Therapy on Serum Cholesterol. *J Am Dietetic Assoc.*, 1991;91:982.

1992

99. Feldmann JE, Jones JE, Weisberg SE, Gandara DR, LYMAN GH, et al.: Advanced Small Cell Lung Cancer Treated With CAV (Cyclophosphamide + Adriamycin + Vincristine) Chemotherapy and the Cardioprotective Agent Dexrazoxane (ADR-529, ICRF-197, Zinecard). *Proc Am Soc Clin Oncol*, 1992;11:296.
100. Spicer DV, Banks P, Reynolds RD, Gams RP, Weisberg SR, Rosenfeld CS, York RM, Jones SE, Khojatch A, Desai AM, Wadler S, Mittleman A, Pendergrass KB, Velez-Garcia E, Mailliard J, Moore JO, Abramsson CJ, Vogel CL, Swain SM, LYMAN GH et al: Radionuclide Resting Left Ventricular Ejection Fraction (LVEF/MUGA) Measurements in Breast Cancer Patients Receiving Adriamycin Based Chemotherapy for Advanced Disease. *Proc Am Soc Clin Oncol.*, 1992;11:91.
101. Rosenfeld CS, Weisberg SR, York RM, Jones SE, Spicer DV, Khojasteh A, Desai AN, Wadler S, Mittleman A, Pendergrass KB, Velez-Garcia E, Moore JO, Abramson N, Vogel CL, Swain SM, LYMAN GH, et al: Prevention of Adriamycin Cardiomyopathy With Dexrazoxane (ADR-529, ICRF-187). *Proc Am Soc Clin Oncol.*, 1992, 11:62.

102. Weisberg SR, Rosenfeld CS, York SE, Spicer DV, Khojasteh A, Desai AN, Wadler S, Mittelman A, Pendergrass KB, Velez-Garcia E, Moore JO, Abramson N, Vogel CL, Swain SM, LYMAN GH, et al: Dexrazoxane, (ADR-529, ICRF-187, Zinecard) Protects Against Doxorubicin Induced Chronic Cardiotoxicity. *Proc Am Soc Clin Oncol*, 1992;11:62.
103. LYMAN GH, Lyman CG, Sanderson R: Cost Analysis of Hematopoietic Growth Factors (HGFs) In Patients Receiving Cancer Chemotherapy (cc). *Proc Am Assn Cancer Res.*, 1992;33:241.
104. Schapira DV, Kumar N, LYMAN GH: Variation in Body Fat Distribution and Cancer Risk Within Families. *Proc Am Soc Clin Oncol*. 1992;11:146.
105. Saba HI, Shamin F, Ismail R, Spiers ASD, LYMAN GH, Ballester OF, Balducci L, Moscinski L, Greene J, Klein C, Sanderson R: Acute Leukemia Transformation of Myelodysplastic Syndrome. *Blood* (supple), 1992;80:459.
106. Saba HI, Ismail R, Shamin F, Spiers ASD, LYMAN GH, Ballester OF, Balducci L, Moscinski L, Greene J, Klein C, Sanderson R: Acute Myeloid Leukemia in the Elderly: An Analysis of 67 Patients. *Blood* (supple), 1992;80:458.
107. Berman B, Liu E, LYMAN GH, Sanderson R, Ballester O: Granulocyte Colony Stimulating Factor (GCSF) in a High Risk Population of Patients with Acute Nonlymphocytic Leukemia (ANLL) Receiving Induction Chemotherapy. *Blood* (supple), 1992;80:446.
108. Schapira DV, Kumar NB, LYMAN GH: Obesity, Body Fat Distribution and Sex Hormones in Breast Cancer Patients. *Current Opinions in Oncology*, 1992.
109. Schapira DV, Kumar NB, LYMAN GH: Obesity, Body Fat Distribution and Sex Hormones in Breast Cancer Patients. *Clinical Digests*, 1992:28-29.
110. Schapira DV, Kumar NB, LYMAN GH: Effects of Duration of Intervention and Locus of Control in Dietary Change. *Yearbook of Family Practice*, Mosby-Yearbook, 1992.
111. Crawford J, Ozer H, Stoller R, Johnson D, LYMAN GH, Tabbara I, Kris R, Grous J, et al. Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer. *Yearbook of Oncology* 1992:178-179.

1993

112. Schapira DV, Kumar NB, LYMAN GH: Variation in Body Fat Distribution and Cancer Risk Within Families. *Clinical Digests*. 1993.

113. LYMAN GH, Balducci L: Overestimation of Disease Risk Associated with Cancer Screening and Diagnostic Tests. *Proc Am Soc Clin Oncol.*, 1993;12:171.
114. LYMAN GH, Lyman SL, Baekey P, Balducci L, Cox C: Prognostic Factors for Breast Cancer Recurrence: Interaction between Tumor Grade and Lymph Node Involvement. *Proc Am Soc Clin Oncol.* 1993;12:88.
115. Stockwell HG, Goldman HL, LYMAN GH, Noss CI, Armstrong SQ, Pinkharm PA, Candelora EC, Brusa MR: Environmental Tobacco Smoke and Lung Cancer Risk in Non Smoking Women. *Yearbook of Oncology*, 1993:34-35.

1994

116. LYMAN GH, Kumar N, Lyman S, Harris J, Balducci L, Reintgen D, Cox C, Sanderson R: Breast Cancer Risk Associated with Cigarette Use in Women. *Prevention* 94, 1994.
117. Spiers A, Ballester O, Saba H, Moscinski L, Sanderson R, Balducci L, LYMAN GH: The CADET Regimen Carboplatin/AraC/Doxorubicin/ Etoposide/Thioguanine): An Active Combination in Poor Prognosis Acute Myeloid Leukemia. *Proc Am Soc Clin Oncol.* 1994;13:307.
118. Werner MH, Phupanich S, LYMAN GH: Rising Incidence of Primary Malignant Brain Tumors in the Elderly in Florida. *Proc Am Assoc Cancer Research*, 1994;35:288.
119. Werner MH, Phupanich S, LYMAN GH: Increasing Incidence of Primary Malignant Brain Tumors in the Elderly in Florida. *J Am Assoc Neurology*, 1994.
120. Lyman S, LYMAN GH, Balducci L, Harris J: Aging and Breast Cancer Recurrence. *Proc American Geriatrics Soc*, 1994:42, SA40.
121. LYMAN GH, Lyman SL, Balducci L, Harris J, Reintgen D, Cox C, Baekey P, Greenberg H: Age and the Risk of Breast Cancer Recurrence . *Proc Am Soc Clin Oncol*, 1994;13:75.
122. Kumar NM, Aziz NM, Schapira DV, Cox CP, LYMAN GH: Weight at Age 30 and Breast Cancer Risk. *Proc Am Soc Clin Oncol.*, 1994;13:169.
123. Spiers A, Ballister O, Saba H, Moscinski L, Sanderson R, Balducci L, LYMAN GH: The CADET Regimen (Carboplatin/ara C/daunorubicin/ etoposide/throguanine): An active combination in poor prognosis acute myeloid leukemia (AML). *Proceedings XVI International Cancer Congress*, New Delhi 1994;274.
124. Saba HI, Nawab US, Nadeem SO, Cosgrove D, Moscinski L, Spiers ASD, Balducci L, LYMAN GH, Zuckerman KS: *Blood* (supple) 1994;84:2482.

125. LYMAN GH, Lyman CG, Sanderson RA, Balducci L: Decision Analysis of Hematopoietic Growth Factor Use in Patients Receiving Cancer Chemotherapy *Yearbook of Oncology*, 1994:403-405.

1995

126. Schapira DV, LYMAN GH, Jarett A, Wolff P, Aziz N: NSAIDS Ingestion and Breast Cancer Prognosis, *Proc Am Soc Clin Oncol*, 1995;14:94.

127. Bensen K, Balducci L, Milok, Heckel L, LYMAN GH: Patients' Perceptions Regarding out-of-Hospital Blood Transfusions. *Proc Am Soc Clin Oncol*. 1995;14:537.

128. Phuphanich S, Werner M. LYMAN GH: Increasing Incidence of Primary Central Nervous System Lymphoma (PCNSL) in the Elderly: Florida Cancer Data Systems (FCDS) *Proc Am Soc Clin Oncol*. 1995;14:185.

129. Miliotes G, LYMAN GH, Rapaport D, Cruse CW, Glass F, Fenske N, Mesira J, Berman C, Reintgen DS: Cutaneous Lymphatic Drainage Patterns in Patients with Grossly Involved Nodal Basins. *J Surgical Oncology* 1995.

130. LYMAN GH, Webster J: The Use of recombinant Human Granulocyte Colony Stimulating Factor (G-CSF) to Reduce Toxicity and Sustain in Dose Intensity in Breast Cancer Patients Receiving Adjuvant Chemotherapy . *Proceedings 2nd International Symposium on Febrile Neutropenia*, Brussels, Belgium 1995.

131. Extermann M, Balducci, LYMAN GH: Prolonging Adjuvant Tamoxifen in Elderly Breast Cancer Patients: Influence of Age, Comorbidities and Various Effectiveness Hypotheses on Life Expectancy and Cost. *Proc 18th Annual San Antonio Breast Cancer Symposium* 1995.

1996

132. LYMAN GH, Kuderer NM, Balducci L: The Decision to Use Colony Stimulating Factors in Patients Receiving Cancer Chemotherapy: Quality-of-Life Adjustment. *Proc AM Soc Clin Oncol*, 1996;15:535.

133. Kuderer NM, Lyman SL, Cox CE, Reintgen DS, Williams CC, LYMAN GH: The Importance of Race for Breast Cancer Survival. *Proc Am Soc Clin Oncol*. 1996;15:114.

134. Kumar NB, Allen KA, Cantor A, Cox C, LYMAN GH, Greenberg H, Shah S: Weight Gain Associated with Tamoxifen: Fact or Artifact? *Cancer Detection and Prevention* 1996;20:508.

135. Kumar NB, LYMAN GH, Allen KA, Cox CE, Shapira DV: Progressive Weight Gain in Women and Breast Cancer Risk: Opportunity of Breast Cancer Prevention. *Cancer Detection and Prevention*; 1996;20:510.

136. Extermann M, Overcash J, LYMAN GH, Parr J, Balducci L: Comparison of the Cumulative Illness Rating Scale –Geriatric (CIRS-6) with the Charleston Comorbidity Scale in Older Cancer Patients. *Proc Cancer in the Elderly*, 1996 Conference, 1996.
137. LYMAN GH, Kuderer NM, Greene J: The Economics of Febrile Neutropenia. *Blood* (supple), 1996 88:346a.
138. LYMAN GH, Kuderer NM, Balducci L: Thresholds for the Use of Recombinant Human Colony-Stimulating Factors (CSFs) Based on Revised Cost Estimated Incorporating Indirect Medical, Non-Medical and Intangible Cost Considerations. *Blood* (supple) 1996 88:346a.

1997

139. LYMAN GH, Kuderer NM, Lyman SL, Debus M, Minton S, Balducci L, Horton J, Reintgen D, Cox C: Survival Following Early versus Late Recurrence of Breast Cancer. *Proc Am Soc Clin Oncol*. 1997 16:181a.
140. Cox CE, Gonzalez R, LYMAN GH: Risk of Disease Recurrence in Patients with Ductal Carcinoma-in-Situ (DCIS) of the Breast Treated with Lumpectomy and Radiation Therapy. *Proc Am Soc Clin Oncol*, 1997;16:152a.
141. Joseph E, Cox CE, Clark R, Ku NN, LYMAN GH, Cantor AA, Minton S, Balducci L, Horton J, DeConti R, Dinwoodie WR, Reintgen DS: Radioguided Surgery for the Ultrastaging of Breast Cancer Patients. *Proc Am Soc Clin Oncol*, 1997; 16:132a.
142. Joseph E, Glass F, Messina J, Cruse CW, Berman C, DeConti R, LYMAN GH, Cantor A, Reintgen DS: Generation of a Mathematical Model to Predict Sentinel Node Involvement in Malignant Melanoma. *Proc Am Soc Clin Oncol*. 1997;16:493a.
143. LYMAN GH, Kuderer NM, Balducci L: A Revised Cost Model for the Use of the Hematopoietic Growth Factors. *Proc 3rd International Symposium on Febrile Neutropenia*, 1997.
144. Benson K, LYMAN GH, Agosti S, Balducci L, Pow-Sang J, Saba H: Estimated Blood Loss in Group O as Compared to Non-group O Radical Prostatectomy Patients. *Blood* (supple) 1997;90:127a.
145. Patterson SG, Benson K, Balducci L, Extermann M, LYMAN GH: Cost Reductive Use of Erythropoietin In Patients with Myelodysplasia. *Blood* (supple) 1997;90:137b.
146. Balducci L, Extermann M, Paterson S, LYMAN GH: Cost-Effectiveness of Pamidronate in the Treatment of Breast Cancer in the Metastatic and in the Adjuvant Setting. *Proc Am Soc Clin Oncol.*, 1998;17:415a.

147. Extermann M, Balducci L, LYMAN GH: What Threshold for Adjuvant Therapy in Older Breast Cancer Patients? *Proc Am Soc Clin Oncol*, 1998;17:102a.
148. Patterson SB, Benson K, Balducci L, Extermann M, LYMAN GH: Cost Reductive Use of Erythropoietin in Patients with Myelodysplasia (MDS). *Proc Am Soc Clin Oncol*, 1998; 17:67a.
149. Extermann M, Balducci L, LYMAN GH: What Threshold for Adjuvant Tamoxifen in Older Breast Cancer Patients? A Decision Analysis. *Europ J Cancer*, 1998;34 (suppl 1): S40.
150. Extermann M, Balducci L, LYMAN GH: What Threshold for Adjuvant Therapy in Older Breast Cancer Patients? *Ann Oncology* 1998; 71:9(S3).
151. Slevin ML, Plowman PN, Ryan CM, Meadows HM, LYMAN GH, Northover JMA: Chemotherapy for Anal Cancer Improves Quality of Life Compared to Radiotherapy Alone. *Proc Am Soc Clin Oncol*. 1998;17:69a.
152. Kuderer NM, Krasner S, Spielberger CD, LYMAN GH: Psychological Measures and Breast Cancer Survival. *Proc Am Soc Clin Oncol*. 1998;17:62a.
153. Ballester O, Moscinski L, LYMAN GH, Perkins J, Eifenbein G, Goldstein S, Sullivan D, Saez R, Fields K: Plasmoblastic Morphology and Proliferative Compartment as Prognostic Indicators for Multiple Myeloma Patients Treated with High-Dose Therapy and Autologous Stem Cell Transplants. *Proc Am Soc Clin Oncol*. 1998;17:19a.
154. Pocock SJ, Henderson RA, LYMAN GH, Chamberlain D: Quality of Life Comparisons of PTCA versus Medical Treatment for Angina: Up to 3 Years Follow-up in the RITA-2 Trial. *Proc European Soc Cardiology*, 1998.
155. LYMAN GH, Clayton T, Pocock SJ, Henderson RA, Chamberlain D: Analysis and Reporting of Health-Related Quality of Life in Clinical Trials: An example using the SF-36 in an Angina Trial. *Proc International Society of Clinical Biostatistics Conference*, Dundee, Scotland, 1998.
156. LYMAN GH: Practice Patterns of Chemotherapy Usage and Associated Neutropenia and Febrile Neutropenia (FN) in Europe. *International Society for Pharmacoeconomics and Outcomes Research*, 1998, Cologne, Germany.
157. LYMAN GH, Kuderer NM, Balducci L: Cost Minimization in the Use of the Colony-Stimulating Factors (CSFs) Based on Clinical Prediction Models (CPMs). *Proc International Society for Pharmacoeconomic and Outcomes Research*, 1998, Cologne, Germany.
158. LYMAN GH, Kuderer NM, Balducci L: The Economics of Febrile Neutropenia. Third International Conference on Febrile Neutropenia, Supportive Care in Cancer, 1998.

1999

159. LYMAN GH: Practice Patterns of Chemotherapy Usage and Associated Neutropenia and Febrile Neutropenia (FN) in Europe. International Society for Pharmacoeconomics and Outcomes Research, Value in Health 1999;2:7.
160. LYMAN GH, Kuderer NM, Balducci L: Cost minimization in the Use of the Colony-Stimulating Factors (CSFs) Based on Clinical Prediction Models (CPMs). International Society for Pharmacoeconomic and Outcomes Research, Value in Health 1999:2:22.
161. Djulbegovic B, Lacevic M, LYMAN GH: Empirical Verification of the Uncertainty Principle in Conducting Randomized Trials: VII Cochrane Colloquium, Rome, Italy, 1999 (awarded Thomas C Chalmers award).
162. Extermann M, Balducci L, LYMAN GH: The Use of Clinical Prediction Models (CPMs) to Improve the Cost Efficiency of Colony-Stimulating Factors (CSFs) in Chemotherapy Patients at Risk for Febrile Neutropenia (FN). Proc Am Soc Clin Oncol 1999 18: 1635.
163. LYMAN GH, Djulbegovic B: Review and Evaluation of Clinical Practice Guidelines in Oncology. Proc Am Soc Clin Oncol 1999; 18: 1646.
164. Djulbegovic B, Fields K, LYMAN GH: Meta-analysis of polymerase chain reaction for BRC-ABL gene rearrangement for the diagnosis of relapse in chronic myelogenous leukemia (CML). Blood 1999 94: 272b.
165. Djulbegovic B, Bennett CL, Lyman GH: Violation of the Uncertainty Principle in Conduct of Randomized Controlled Trials (RCTs) of Erythropoietin (EPO). Blood 1999: 94: 399a.

2000

166. LYMAN GH, Kuderer NM: Djulbegovic: Meta-Analysis of Granulocyte Colony-Stimulating Factor to Prevent Febrile Neutropenia in Patients Receiving Cancer Chemotherapy. Proc Am Soc Clin Oncol 2000; 19: 55a.
167. Kumar N, Riccardi D, Allen K, Cantor A, Jacobsen P, Horton J, Minton S, Balducci L, LYMAN G: Weight Gain in Breast Cancer Patients on Chemotherapy. Exploring Hormonal, Body Composition and Behavioral Mechanisms. 5th International Symposium on Predictive Oncology and Therapy (ISPO), 2000.
168. Li W, Reintgen DR, LYMAN GH: Impact of Sentinel Lymph Node Histology and RT-PCR on Disease-Free Survival, Proc Am Assoc Cancer Res 2000; 41: 392.
169. Teng S, Powers BS, Cruse W, Glass F, Messina J, Reintgen D, LYMAN GH: Validation of the Proposed New AJCC Staging System for Patients with Malignant Melanoma. Proc Soc Surg Oncol 2000 (in press).

170. B. Djulbegovic, M. Lucevic, I. Hozo, C.L. Bennett and G.H. Lyman: Critical Appraisal Of Randomized Controlled Trials In Myeloma (Published From 1966-1998). Proc Am Soc Clin Oncol 2000; 19: 444a.
171. Djulbegovic B, Lucevic M, Macy T, Adams J, Lyman GH: What is the probability that results of meta-analyses will favor innovative treatments? Proc VIII Cochrane Colloquium, Capetown, South Africa, 2000.
172. Crawford J, Dale D, Lyman GH: Suboptimal Dosing in Adjuvant Breast Cancer Chemotherapy: Evidence from a Nationwide Survey. Breast Cancer Research and Treatment 2000; 64: 66.
173. Jared R. Adams, Gary H. Lyman, Ben Djulbegovic, Charles L. Bennett: A RADICAL CHANGE IN CSF RECOMMENDATIONS SUPPORTING DECREASE OF CSF USE IN SECONDARY PROPHYLAXIS OF NON-CURABLE CANCERS: WILL PHYSICIANS RESPOND, Blood 2000; 95:

2001

174. GH Lyman, Crawford J, Dale D, Chen H, Agboola Y, Lininger L for the ANC Study Group: Clinical Prediction Models for Febrile Neutropenia (FN) and Relative Dose Intensity (RDI) in Patients Receiving Adjuvant Breast Cancer Chemotherapy. Proc Am Soc Clin Oncol 2001; 20: 394A.
175. Dale D, Crawford J, LYMAN for the Steering Committee of the ANC Study Group Chemotherapy-Induced Neutropenia and Associate Complications in Randomized Clinical Trials: An Evidence-Based Review. Proc Am Soc Clin Oncol 2001; 20; 410a.
176. L Lininger, J Crawford, D Dale, H Chen, Y Agboola, E Stump, P Evans, and GH Lyman for the ANC Study Group: PREDICTING RISK OF NEUTROPENIC COMPLICATIONS: A POINT-OF-CARE ASSESSMENT TOOL. Proc Am Soc Clin Oncol 2001; 20: 411a.
177. M Wallam, Y Agboola, GH Lyman: META-ANALYSIS OF COLONY-STIMULATING FACTORS (CSFs) TO TREAT CHEMOTHERAPY (CT)-RELATED FEBRILE NEUTROPENIA (FN). Proc Am Soc Clin Oncol 2001; 20: 2975.
178. V Sivasubramaniam, D Dale, J Crawford, Y Agboola, GH Lyman for the ANC Study Group: IMPACT OF OUTPATIENT TREATMENT OF FEBRILE NEUTROPENIA (FN) ON RISK THRESHOLDS FOR G-CSF PROPHYLAXIS IN CANCER CHEMOTHERAPY (CT). Proc Am Soc Clin Oncol 2001; 20: 392a.
179. Crawford J, Dale D, LYMAN GH: Chemotherapy-Induced Neutropenia and Associated Complications in Randomized Clinical Trials for Non-Hodgkin's Lymphoma. PanPacific Conferences on Lymphomas 2001.

180. Dale DC, Crawford J, Lyman GH for the ANC Study Group. Improved Reporting of Delivered Dose Intensity Is Needed in Randomized Clinical Trials of Chemotherapy in Non-Hodgkin's Lymphoma (NHL). *Blood*, 2001; 240b.
181. Gary H Lyman, Ernst Berndt, William Crown, Joel Kallich, Haim Erder, Stan Finkelstein. Anemia is Associated With High Cost in Newly Diagnosed Cancer Patients. *Blood* 2001; 414b.
182. Gary H Lyman, Christopher H. Lyman, David Dale, Jeffrey Crawford for the ANC Study Group. Risk Models for the Prediction of Chemotherapy-Induced Neutropenia (CIN) and its Consequences: A Systematic Review and Classification. *Blood* 2001; 413b.
183. Lyman GH, Kuderer NM, Agboola O, Crawford J, Dale D for the ANC Study Group. The Epidemiology and Economics of Neutropenia in Hospitalized Cancer Patients: Data from the University HealthSystem Consortium. *Blood* 2001; 432a.
184. Gary. H. Lyman, David Dale, Jeffrey Crawford, Brad Stolshek, William Carter and David Delgado. Risk of Febrile Neutropenia Among Patients Receiving CHOP Chemotherapy. *Blood* 2001; 230b.

2002

185. Cosler LE, Agboola O, Calhoun EA, LYMAN GH: AN UPDATED RISK THRESHOLD MODEL FOR G-CSF PROPHYLAXIS USE IN CANCER CHEMOTHERAPY: INCORPORATION OF PATIENT OUT-OF-POCKET AND INDIRECT COSTS, *Value in Health* 2002; 5: 138.
186. Kuderer NM, Cosler L, Crawford J, Dale DC, LYMAN GH: Cost and Mortality Associated with Febrile Neutropenia in Adult Cancer Patients. *Proc Am Soc Clin Oncol* 2002; 21: 250a.
187. LYMAN GH, Morrison VA, Dale DC, Crawford J, Delgado D, Fridman M: Risk of First Febrile Neutropenia (FN) among Patients Receiving CHOP Chemotherapy. *Proc Am Soc Clin Oncol* 2002; 21: 358a.
188. Kim T, Agboola O, LYMAN GH: Lymphatic Mapping and Sentinel Lymph Node Sampling in Breast Cancer: a Meta-analysis. *Proc Am Soc Clin Oncol* 2002; 21: 36a.
189. Agboola O, Crawford J, Dale DC, Erder H, Fridman M, Salvado A, Brannan C, LYMAN GH: Risk Models for Neutropenic Complications Associated with Breast Cancer Adjuvant Chemotherapy. *Proc Am Soc Clin Oncol* 2002; 21: 66a.
190. Dale DC McCarter G, Crawford J, LYMAN GH: Delivered Dose Intensity in Randomized Clinical Trials (RCTs) Of Chemotherapy in Early-Stage Breast Cancer (ESBC) and Non-Hodgkin's Lymphoma (NHL): A Need for Improved Reporting. *Proc Am Soc Clin Oncol* 2002; 21: 252a.

191. Leichman CG, LYMAN GH, Remedios P et al: Molecular Biologic Correlates with Continuous Infusion 5-FU or Cepecitabine in Disseminated Colorectal Cancer. Proc Am Soc Clin Oncol 2002; 21: 431a.
192. Berndt E, Crown B, Finkelstein S, Kallich J, Erder H, LYMAN GH: Labor Force Activity in Cancer Patients with Anemia. Proc Am Soc Clin Oncol 2002; 21: 192b.
193. Finkelstein S, Berndt E, Crown W, Kallich J, Erder H, LYMAN GH: Anemia as a Predictor of High Cost in Recently Diagnosed Cancer Patients. Proc Am Soc Clin Oncol 2002; 21: 199b.
194. Ansari RH, Glaspy JA, Lu J, Ciesla GN, Schmier JK, Sommer T, Ramnes CR, LYMAN GH: Assessing Medication Related Disruption of Life: Results from a Survey of Patients Receiving Prophylactic Filgrastim to Prevent Chemotherapy-Induced Neutropenia. Proc Am Soc Clin Oncol 2002; 21: 201b.
195. Kuderer NM, Cosler LE, Crawford J, Dale, DC, LYMAN GH: Cost Distribution and Length of Stay Associated with Febrile Neutropenia in Adult Cancer Patients. Supportive Care in Cancer 2002; 10: 372.
196. LYMAN GH, Berndt E, Crown WH, Kallich J, Erder MH, Finkelstein S: Anemia is a Predictor of High Cost in Patients Recently Diagnosed with Cancer. Supportive Care in Cancer 2002; 10: 365.
197. Berndt E, Crown WH, Finkelstein S, Kallich J, Erder MH, LYMAN GH: Estimating the Impact of Cancer and Anemia on Workplace Absence in Employee Cancer Patients and Employee Caregivers of Patients with Cancer. Supportive Care in Cancer 2002; 10: 366.
198. LYMAN GH, Delgado D: Risk and Timing of Hospitalization for Febrile Neutropenia among Patients Receiving CHOP-Like Regimens for Intermediate-Grade Non-Hodgkin's Lymphoma. Blood 2002; 100: 780a.
199. Agboola O, Balducci L, Dale D, Crawford J and LYMAN GH: Efficacy of the Colony-Stimulating Factors (CSFs) in Elderly Patients with Aggressive Non-Hodgkin's Lymphoma (NHL): A Systematic Review. Blood 2002; 100: 779a.
200. Kuderer NM, Crawford J, Dale D, LYMAN GH: Febrile Neutropenia (FN) in Adult Lymphoma Patients is Associated with Substantial Mortality and Cost. Blood 2002; 100: 875a.
201. Ansari RH, Glaspy JA, Lu ZJ, Sommer T, Lee H, Haithcox S, Ramnes C, Ciesla GN, LYMAN GH: Assessing the Impact of Frequent Injections on Patient Life: Results from a Survey of Patients Receiving Prophylactic Filgrastim for Chemotherapy-Induced Neutropenia (CIN). Blood 2002; 100: 500b.
202. Glaspy JA, Meehan K, Lu ZJ, Ansari RH, Brown R, Erder MH, Kallich J, Lee H, LYMAN GH: A Model to Estimate the Provider Cost Savings of Switching to Long Acting

Cytokines for Anemia and Neutropenia in Patients Undergoing Chemotherapy Treatment. *Blood* 2002; 100: 500b.

203. Colony-Stimulating Factor (CSF) Treatment of Patients with Chemotherapy-Induced Febrile Neutropenia (FN): A Meta-analysis of the Randomized Clinical Trials (RCTs). *Blood* 2002 100: 174b.
204. LYMAN GH, Djulbegovic B, Kuderer NM, Dale D, Crawford J: Colony-Stimulating Factors (CSFs) for Established Febrile Neutropenia (FN) Revisited: An Economic Analysis Based on a Meta-Analysis of Randomized Controlled Trials (RCTs). *Blood* 2002 100: 502b.
205. Dale D, Wolff D, Agboola O, Crawford J, LYMAN GH: Prospective Patient Registry for the Development of Risk Models of Neutropenic Complications Including Febrile Neutropenia (FN). *Blood* 2002: 502b.
206. Kim T, Agboola O, LYMAN GH: The Predictive Value of Sentinel Lymph Node Sampling in Breast Cancer Staging: A Meta-Analysis. *Breast Cancer Research and Treatment* 2002; 76: S126.
207. LYMAN GH, Crawford J, Dale D and Wolf D: Predicting the Risk of Chemotherapy-Induced Neutropenia (CIN) in Patients With Breast Cancer: Rationale for Prospective Risk Model Development. *Breast Cancer Research and Treatment* 2002; 76: S537.

2003

208. LYMAN GH, Kuderer NM, Crawford J and Dale D: Economic Impact of Pegfilgrastim Use Based on the Risk of Febrile Neutropenia (FN) in NHL Patients with CHOP. *Proc Am Soc Clin Oncol* 2003; 22: 593.
209. Kuderer NM, Cosler L, Crawford J, Dale D and LYMAN GH: Mortality and Economic Impact of Hospitalization with Febrile Neutropenia in Patients with Breast Cancer. *Proc Am Soc Clin Oncol* 2003; 22: 27.
210. Agboola O, Crawford J, Dale D, LYMAN GH: Most Patients Treated with Adjuvant Chemotherapy for Breast Cancer Receive Substantially Reduced Dose Intensity: Results of Practice Pattern Survey of Nearly 20,000 Patients. *Proc Am Soc Clin Oncol* 2003; 22: 28.
211. Clark O, Djulbegovic B, Dale D, Crawford J, LYMAN GH: Treatment with Colony-Stimulating Factors Improves Clinical Outcomes in Patients with Established Febrile Neutropenia: A Meta-Analysis of the Randomized Clinical Trials. *Proc Am Soc Clin Oncol* 2003; 22: 172.
212. Cosler L, Djulbegovic B, Kuderer NM, Dale D, LYMAN GH: Colony-Stimulating Factor Treatment of Established Febrile Neutropenia Reduces Overall Costs: Results of an

Economic Model Based on a Meta-Analysis of Randomized Controlled Trials. Proc Am Soc Clin Oncol 2003; 22: 526.

213. Sahasrabudhe DM, McMahon B, Brasacchio R, Messing E, O'Keefe R, Puzas E, Rosier R, LYMAN G: Effect of Androgen-Ablation on Bone Resorption in Prostate Cancer. Proc Am Soc Clin Oncol 2003; 22: 414.
 214. Newman CL, Shin S-U, Cho H-M, Logan-Young W, LYMAN GH: Presence of Autologous anti-HER2/neu antibodies in women with ductal carcinoma in situ (DCIS) and women with invasive breast cancer. Proc Am Soc Clin Oncol 2003; 22: 875
 215. Blumberg N, Zhao H, Messing S, Heal JM, LYMAN GH: Misapplication of the Intention-to-Treat Principle in Clinical Trials and Meta-analyses of Leukoreduced Blood Transfusions in Surgical Patients. Blood 2003; 102: 562a
 216. Crawford J, Dale D, Wolff D, Agboola O, Culakova E, LYMAN GH: Risk of Neutropenic Complications in Patients Receiving Systemic Chemotherapy: Prospective Risk Model Development. Blood 2003; 102: 168b
 217. Dubois RW, Badamgarav E, Bernal M, Song P, LYMAN GH: Optimizing the Use of Colony-Stimulating Factors in Reducing the Risk of Febrile Neutropenia. Blood 2003; 102: 169b
 218. LYMAN GH, Bernal M, Badamagarav E, Pinto L, Dubois RW: Pegfilgrastim vs. Filgrastim in Reducing the Risk of Febrile Neutropenia. Blood 2003; 102: 170b
 219. Dale D, Crawford J, Wolff D, Agboola O, Culakokva E, LYMAN GH: Predicting the Risk of Chemotherapy-Induced Neutropenia in Patients with Non-Hodgkin's Lymphoma: Prospective Risk Model Development. Blood 2003; 102: 305b
 220. GH LYMAN, O Agboola, J Crawford, DC Dale: Most Patients Treated with Adjuvant Chemotherapy for Breast Cancer Receive Substantially Reduced Dose Intensity. Supp Care Cancer 2003; 11; 815.
 221. Griggs JJ, Sorbero MS, LYMAN GH: Variation in adjuvant breast cancer chemotherapy dosing in overweight and obese women. Supp Care Cancer 2003; 11;
 222. NM Kuderer, J Crawford, D Dale, GH LYMAN: Complications and Cost Associated with Febrile Neutropenia in Hospitalized Adult Cancer Patients. Supp Care Cancer 2003; 11; 817.
- 2004**
223. D Dale, J Crawford, O Agboola, GH LYMAN for the ANC Study Group Febrile Neutropenia and Reduced Dose Intensity in Patients with Aggressive Non-Hodgkin's Lymphoma (NHL) Treated with CHOP and CNOP. Proc ASCO 2004; 23: 580.

224. NM. Kuderer*,¹ J Crawford*,² D Dale³, GH LYMAN¹ for the ANC Study Group Complications and Costs Associated with Febrile Neutropenia in Hospitalized Adult Cancer Patients. Proc ASCO 2004; 23: 529.
225. E Culakova¹, A Khorana¹, N. Kuderer,¹ J Crawford,² D Dale³, GH LYMAN¹ for the ANC Study Group Hospitalization with Febrile Neutropenia in Colorectal Cancer Patients. Proc ASCO 2004; 23: 296.
226. DB Daniel¹, J Crawford¹, NM Kuderer², DC Dale³, GH LYMAN² for the ANC Study Group Risk and Mortality Associated with Febrile Neutropenia in Lung Cancer Patients. Proc ASCO 2004; 23: 668.
227. SK Basu, ID Fernandez, SG Fisher, BL Asselin, GH LYMAN; University of Rochester, NY Study of mortality associated with febrile neutropenia among children with cancer. Proc ASCO 2004; 23: 801.
228. GH LYMAN, J Crawford, D Dale, DA Wolf D, E Culakova for the ANC Study Group Predicting the Risk of Neutropenic Complications and Reduced Dose Intensity in Patients With Early-Stage Breast Cancer (ESBC): Results from a Prospective Nationwide Registry. Proc ASCO 2004; 23: 70.
229. D Wolff,¹ J Crawford*,² DC Dale³, MS Poniewierski and GH LYMAN*,¹ for the ANC Study Group Risk of Neutropenic Complications Based on a Prospective Nationwide Registry of Cancer Patients Initiating Systematic Chemotherapy. Proc ASCO 2004; 23: 547.
230. AA Khorana, E Culakova, GH LYMAN, CW Francis for the ANC Study Group Incidence Of Thromboembolic Events In A Prospective Nationwide Registry Of Cancer Patients Initiating Systemic Chemotherapy. Proc ASCO 2004; 23: 730.
231. R Komrokji, E Dib, G Phillips, J Liesveld and GH LYMAN University of Rochester, Rochester, NY Use of Colony-Stimulating Factors (G-CSF and GM-CSF) After Allogeneic Stem Cell Transplantation in Adult Patients: A Meta-Analysis of Published Studies. Proc ASCO 2004; 23: 590.
232. E. Badamgarav, G. LYMAN, L. Pinto, M. Bernal, B. Dubois; Zynx Health, Beverly Hills, CA; University of Rochester Medical Center, Rochester, NY Efficacy of GM-CSF Vs G-CSF in Reducing Chemotherapy-Induced Complications (CIC): A Systematic Review of Literature. Proc ASCO 2004; 23: 551.
233. B. Dubois, L. Pinto, E. Badamgarav, M. Bernal, G. LYMAN Review of Special Populations for the Use Of Colony-Stimulating Factors. Proc ASCO 2004; 23: 554.
234. LE Cosler, J Hornberger, GH LYMAN Economic Analysis of Targeting Chemotherapy (CT) Using a 21 Gene RT-PCR Assay in Lymph Node Negative (LN-), Estrogen Receptor Positive (ER+) Early-Stage Breast Cancer (ESBC). Proc ASCO 2004; 23: 526.

235. A Eldar-Lissai, LE Cosler, GH Lyman: Economic Analysis of Prophylactic Pegfilgrastim in Cancer Patients Receiving Chemotherapy. *Blood* 2004; 104: 238 (abstract 2212).
236. J Crawford, DA Wolff, E Culakova, MS Poniewierski, C Selby, DC Dale, GH Lyman, First Cycle Risk of Severe and Febrile Neutropenia in Cancer Patients Receiving Systemic Chemotherapy: Results from a Prospective Nationwide Study. *Blood* 2004; 104: 238 (abstract 2210).
237. B Wittman, JT Horan, GH Lyman: Prophylactic Colony-Stimulating Factors in Pediatric Patients Receiving Myelosuppressive Chemotherapy: A Meta-Analysis of Randomized Controlled Trials. *Blood* 2004; 104: 238 (abstract 2211).
238. DC Dale, JH Goldschmidt, J Crawford, GH Lyman: Reduced Relative Dose Intensity (RDI) in Patients with Aggressive Non-Hodgkin's Lymphoma (NHL) *Blood* 2004; 104: 296 (abstract 3314).
239. NM Kuderer, J Crawford, DC Dale, GH Lyman: Validation of a Risk Model for Hospitalized Adult Cancer Patients with Febrile Neutropenia. *Blood* 104; 29 (abstract 89).
240. GH Lyman, G Rossi, J Glaspy: Assessment of Clinical Outcomes Following Erythropoietic Intervention at a Hemoglobin Concentration Above 10 g/dL: A Comprehensive Review of Recent Literature. *Blood* 104;
241. NM Kuderer, AA Khorana, JW Friedberg, E Culakova, GL Phillips, CW Francis, GH Lyman: Incidence and Risk Factors for Thromboembolism in Patients with Hematologic Malignancies undergoing Allogeneic and Autologous Stem Cell Transplantation. *Blood* 104; 183 (abstract 1141).
242. RS Komrokji, NP Uppal, AA Khorana, MD, GH Lyman, KL Kaplan, RI Fisher, CW Francis: Venous Thromboembolic Events in Patients with Diffuse Large B cell Non-Hodgkin's lymphoma. *Blood* 104;
243. AA Khorana, CW Francis, E Culakova, R Komrokji, N Uppal, GH Lyman: A Predictive Model For Chemotherapy-Associated Thrombosis Based On Findings From A Prospective Outpatient Registry. *Blood* 104; 258 (abstract 2586).
244. AA Khorana, CW Francis, E Culakova, GH Lyman: Thrombocytosis Increases The Risk Of Chemotherapy-Associated Thrombosis. *Blood* 104; 120 (abstract 282).
245. AA Khorana, CW Francis, E Culakova, RI Fisher, N Kuderer, GH Lyman: Thromboembolism In Hospitalized Neutropenic Cancer Patients. *Blood* 104; 237 (abstract 2199).

246. GH Lyman, NM Kuderer: Gene Expression Profile Signatures to Predict Survival in Diffuse Large B-cell Lymphoma: A Meta-Analysis of Early Results. *Blood* 104; 241 (abstract 2274).
247. SS Kuthiala, GH Lyman, OF Ballester: Hematopoietic Stem Cell Transplantation Phase III Clinical Trials for patients with hematological malignancies in the US: lessons to be learned from the European experience. *Blood* 104; 116 (abstract 229).
248. N Tahir, JH Goldschmidt, E Culakova, MS Poniewierski, DA Wolff, DC Dale, J Crawford, GH Lyman: Assessment of Hematologic and Non-Hematologic Toxicity in Older Cancer Patients Receiving Systemic Chemotherapy: Results from a Prospective Nationwide Registry. *Blood* 104; 287 (abstract 3131).
249. DC Dale, J Crawford, DA Wolff, MS Poniewierski, E Culakova, GH Lyman: Predicting the Risk of Neutropenic Complications and Reduced Dose Intensity in Patients With Malignant Lymphoma: Results from a Prospective Study. *Blood* 104;
250. GH Lyman, J Crawford, DC Dale: Predictors of reduced relative dose intensity (RDI) in patients with early-stage breast cancer (ESBC) receiving adjuvant chemotherapy (CT). *Breast Cancer Research and Treatment* 2004; S49 (abstract 1025).
251. GH Lyman, NM Kuderer: Gene expression profiles as predictors of recurrence-free survival (RFS) in early-stage breast cancer (ESBC): a meta-analysis early results. *Breast Cancer Research and Treatment* 2004; S20 (abstract 101).
252. GH Lyman, LE Cosler, J Hornberger. A 21-gene RT-PCR assay in lymph node negative (LN-), estrogen receptor positive (ER+) early-stage breast cancer (ESBC): an age-specific economic analysis. *Breast Cancer Research and Treatment* 2004; S103 (abstract 2081).
253. GH Lyman, DA Wolff, E Culakova, MS Poniewierski, DC Dale, J Crawford. Factors associated with reduced dose intensity in patients receiving adjuvant chemotherapy for early-stage breast cancer (ESBC). *Breast Cancer Research and Treatment* 2004; S60 (abstract 1057).
254. GH Lyman, TY Kim, AE Giuliano. A systematic review and meta-analysis of lymphatic mapping and sentinel node biopsy (SNB) in early-stage breast cancer (ESBC). *Breast Cancer Research and Treatment* 2004; S77 (abstract 2001).

2005

255. LE Cosler, A Eldar-Lissai, DC Dale, J Crawford, GH Lyman. Economic analysis of pegfilgrastim in patients receiving cancer chemotherapy. *J Clin Oncol* 2005; 23: 538s (abstract 6041).

256. NM Kuderer, J Crawford, DC Dale, GH Lyman. Meta-analysis of prophylactic granulocyte colony-stimulating factor (G-CSF) in cancer patients receiving chemotherapy. *J Clin Oncol* 2005; 23: 758s (abstract 8117).
257. GH Lyman, J Crawford, DA Wolff, E Culakova, MS Poniewierski, DC Dale. A risk model for first cycle febrile neutropenia in cancer patients receiving systemic chemotherapy. *J Clin Oncol* 2005; 23: 759s (abstract 8122).
258. G Rossi, J Glaspy, GH Lyman: Are there clinical benefits associated with treatment of mild chemotherapy-induced anemia (CIA)? A Systematic Review. *J Clin oncol* 2005; 23: 777s (abstract 8194)
259. G Lyman, G Rossi, J Glaspy: Does the Treatment of Mild Anemia Result in Improved Clinical Outcomes? Examining the Benefits of Early Erythropoietic Intervention in Patients with Chemotherapy-Induced Anemia. *Supportive Care in Cancer* 2005; 13: 410 (Abstract 02-009)
260. J Crawford, D Dale, D Wolff, E Culakova, M Poniewierski, G Lyman: Risk of Neutropenic Events During the First Cycle of Systemic Cancer Chemotherapy: Results from a Prospective Study. *Supportive Care in Cancer* 2005; 13: 425 (Abstract 06-049)
261. N Kuderer, J Crawford, D Dale, G Lyman: A Validated Risk Model for Mortality in Hospitalized Adult Cancer Patients with Febrile Neutropenia. *Supportive Care in Cancer* 2005; 13: 425-426 (Abstract 06-050)
262. G Lyman, J Crawford, D Wolff, E Culakova, M Poniewierski, D Dale. A Prospective Risk Model for First Cycle Febrile Neutropenia in Cancer Patients Receiving Systemic Chemotherapy. *Supportive Care in Cancer* 2005; 13: 426-427 (Abstract 06-052)
263. G Lyman, N Kuderer, J Crawford, D Dale: Prophylactic Granulocyte Colony-Stimulating Factor in Cancer Patients Receiving Chemotherapy: A Meta-Analysis. *Supportive Care in Cancer* 2005; 13: 429 (Abstract 07-059)
264. G H Lyman, MD, MPH¹, N M Kuderer, MD¹, M Shayne, MD¹, D C Dale, MD², D Wolff, MS, PCNP¹, E Culakova, Ph.D.¹, M S Poniewierski, MD, MS¹ and J Crawford: A Prospective Risk Model for Neutropenic Complications in Early-Stage Breast Cancer Patients Receiving Adjuvant Chemotherapy. *Breast Cancer Research and Treatment* 2005
265. G H Lyman, MD, MPH¹, M Rader, MD², D Wolff, MS, PCNP¹, E Culakova, PhD¹, B Ding, PhD³, R Dansey, MD³ and H Ozer, MD⁴: Comparison of outcomes in patients receiving standard community care while enrolled on a nationwide registry with those enrolled in a prospective nationwide community-based clinical trial. *Breast Cancer Research and Treatment* 2005.

266. J J Griggs, MD, MPH¹, M S Sorbero, PhD,MS², E Culakova, PhD¹ and G H Lyman, MD, MPH¹The impact of educational attainment on initial doses of breast cancer adjuvant chemotherapy. Breast Cancer Research and Treatment 2005.
267. Michelle Shayne, MD^{1,4}, Eva Culakova, Ph.D^{1,4}, Marek S Poniewierski, MD, MS^{1,4}, Debra Wolff, MS, PCNP^{1,4}, David C Dale, MD^{2,4}, Jeffrey Crawford, MD^{3,4} and Gary H Lyman, MD, MPH^{1,4}: Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. Blood 2005; 106: 874a.
268. Gary H Lyman, MD, MPH^{1,4}, Jeffrey Crawford, MD^{2,4}, Debra Wolff, MS, PCNP^{1,4*}, Eva Culakova, PhD^{1,4}, Marek S Poniewierski, MD, MS^{1,4*} and David C Dale, MD^{3,4}.A Prospective Risk Model for Neutropenic Complications in Patients with Malignant Lymphoma. Blood 2005; 106: 930a.
269. Gary H Lyman, MD, MPH^{1,4}, Brandon McMahon, MD^{1*}, Nicole M Kuderer, MD^{1,4*}, Jeffrey Crawford, MD^{2,4}, Debra Wolff, MS, PCNP^{1,4*}, Eva Culakova, PhD^{1,4}, Marek S Poniewierski, MD, MS^{1,4*} and David C Dale, MD^{3,4}. A Risk Model for Chemotherapy-Induced Anemia (CIA) in Cancer Patients. Blood 2005; 106: 223a.

2006

270. Gary H Lyman, Adi EldarLissai, Leon Cosler Cost-Effectiveness Analysis of G-CSF Support Elderly Patients with Aggressive Non-Hodgkins Lymphoma Receiving CHOP. International Society for Pharmacoeconomic and Outcomes Research 2006; Value in Health 2006; Value in Health: A107.
271. L. E. Cosler, N. M. Kuderer, J. Hornberger, G. H. Lyman; 21-gene RT-PCR assay in lymph node negative (LN-), estrogen receptor positive (ER+) breast cancer: an economic analysis including prognostic and predictive information. J Clin Oncol 2006; 24; 307s (abstract 6024).
272. G. H. Lyman, N. M. Kuderer, J. Crawford, D. A. Wolff, E. Culakova, M. S. Poniewierski, D. C. Dale: Prospective validation of a risk model for first cycle neutropenic complications in patients receiving cancer chemotherapy. J Clin Oncol 2006; 24, 483s (abstract 8561)
273. Nicole M. Kuderer¹, Charles W. Francis¹, Jeffrey Crawford², David C. Dale³, Debra Wolff¹, Eva Culakova¹, Marek S. Poniewierski¹, Gary H. Lyman¹: A Prediction Model for Chemotherapy-Associated Thrombocytopenia in Cancer Patients. J Clin Oncol 2006; 24; 497s (abstract 8616).
274. D. C. Dale, L. E. Cosler, D. A. Wolff, E. Culakova, M. S. Poniewierski, J. Crawford, G. H. Lyman: Economic analysis of prophylactic granulocyte colony-stimulating factor (G-CSF) use based on a risk model for neutropenic complications in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 2006; 24; 327s (abstract 6107).

275. E. Culakova, J. J. Griggs, M. E. Sorbero, D. A. Wolff, M. S. Poniewierski, G. H. Lyman; Non-clinical factors associated with intentionally reduced breast cancer chemotherapy doses. *J Clin Oncol* 2006; 24; 306s (abstract 6020).
276. J Griggs, E Culakova, M Sorbero, J Crawford, DC Dale, DA Wolff, MS Poniewierski, GH Lyman: Social and Racial Disparities in the Use of Non-Standard Breast Cancer Adjuvant Chemotherapy Regimens. *J Clin Oncol* 2006; 24: 310s (abstract 6036).
277. S. A. Ferro, L. E. Cosler, D. A. Wolff, M. S. Poniewierski, E. Culakova, A. A. Khorana, G. H. Lyman: Variation in the cost of treatment for colorectal cancer. *J Clin Oncol* 2006; 24: 176s (abstract 3625).
278. Extermann M, Boler I, O'Neill E, Brown R, Defelice J, Levine R, Lubiner E, Schreiber F, LYMAN GH, Balducci L: Muscle Weakness is a Significant Problem in Older Patients Receiving Chemotherapy. *J Clin Oncol* 2006; 24: 479s (abstract 8545).
279. Kuderer N, Francis C, Crawford J, Dale D, Wolff D, Culakova E, Poniewierski M, LYMAN G: Chemotherapy-Associated Thrombocytopenia: A Conditional Prediction Model. *Supp Care Cancer* 2006; 14: 606 (abstract 06-038).
280. LYMAN G, Kuderer N, Crawford J, Wolff D, Culakova E, Poniewierski M, Dale D: Validation of a Risk Model for Early Neutropenic Complications in Patients Receiving Cancer Chemotherapy. *Supp Care Cancer* 2006; 14: 607 (abstract 06-041).
281. LYMAN GH, Dale DC, Kuderer NM, Wolff D, Culakova E, Poniewierski MS, Crawford J: Prospective Validation of a Predictive Model for Early Anemia in Patients Receiving Cancer Chemotherapy. 48th Annual Meeting of the American Society of Hematology Blood 2006 (in press).
282. Michelle Shayne, MD¹, Eva Culakova, PhD¹, Debra A Wolff, MS, PNCP¹, Marek S Poniewierski, MD, MS¹ and Gary H Lyman, MD, MPH¹. Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy. 29th Annual San Antonio Breast Cancer Symposium. *Breast Cancer Research and Treatment* 2006 (in press).
283. Gary H Lyman, MD, MPH, FRCP¹, Nicole M Kuderer, MD¹, Jeffrey Crawford, MD², Debra A Wolff, MS, PCNP¹, Eva Culakova, Ph.D¹, Marek S Poniewierski, MD, MS¹ and David C Dale, MD³. Prospective validation of a risk model for first cycle neutropenic complications in early-stage breast cancer patients receiving adjuvant chemotherapy. 29th Annual San Antonio Breast Cancer Symposium. *Breast Cancer Research and Treatment* 2006 (in press).
284. Shayne M, Culakova E, Dale DC, Crawford J, Poniewierski MS, Wolff DA, Lyman GH: Hematologic Toxicity in Older Cancer Patients Undergoing Systemic Chemotherapy. 7th Annual Meeting of SIOG 2006 (in press).

285. Shayne M, Culakova E, Poniewierski MS, Wolff DA, Dale DC, Crawford J, Lyman GH: A Risk Model for First Cycle Neutropenic Events in Older Cancer Patients Receiving Systemic Chemotherapy. 7th Annual Meeting of SIOG 2006 (in press).
286. G.H. Lyman, N.M. Kuderer, M.S. Poniewierski, J. Crawford, D.A. Wolff, E. Culakova, D.C. Dale for the ANC Study Group; Factors Associated with Reductions in Chemotherapy Dose Intensity: Impact of Clinical, Sociodemographic and Practice Setting. *J Clin Oncol* 2007; 25: 334s.
287. Khorana AA, Francis CW, Culakova E, Kuderer NM, LYMAN GH: Increasing Risk for Venous Thromboembolism Among Hospitalized Cancer Patients. *J Clin Oncol* 2007; 25: 495s.
288. Michelle Shayne¹, Eva Culakova^{1,4}, David Dale^{2,4}, Marek Poniewierski^{1,4}, Debra Wolff^{1,4}, Jeffrey Crawford^{3,4}, Gary Lyman^{1,4} A Validated Risk Model for Early Neutropenic Events in Older Cancer Patients Receiving Systemic Chemotherapy. *J Clin Oncol* 2007; 25: 502s.
289. Jessica M Kleiner¹, Eva Culakova^{1,4}, David C Dale^{2,4}, Jeffrey Crawford^{3,4}, Marek S Poniewierski^{1,4}, Debra A Wolff^{1,4}, Gary H Lyman^{1,4}. Risk factors for hospitalization in elderly cancer patients receiving chemotherapy. *J Clin Oncol* 200; 25: 501s.
290. Nicole M. Kuderer, Alok A. Khorana, Gary H. Lyman, and Charles W. Francis: A Meta-Analysis and Systematic Review of Anticoagulants as Cancer Treatment: Impact on Survival and Bleeding Complications in Cancer Patients. *J Clin Oncol* 2007; 25: 510s.
291. J Crawford, DC Dale, NM Kuderer, DA Wolff, E Culakova, MS Poniewierski, GH LYMAN: Risk model for neutropenic complications in lung cancer patients receiving cancer chemotherapy. *Supportive Care in Cancer* 2007; 15: 762.
292. Ramsey SD, Liu Z, Boer R, Malin JL, Sullivan SD, Doan QV, Dubois RW, LYMAN GH: Primary Prophylaxis of Febrile Neutropenia with Pegfilgrastim is Cost-Effective Compared to Secondary Prophylaxis for Women with Early-Stage Breast Cancer Receiving Chemotherapy. *Value in Health* 2007; 10: A125.
293. Pettengell R, Skacel T, Aapro M, Duehrsen U, Easton V, LYMAN G: Pegfilgrastim provides effective primary prophylaxis against febrile neutropenia in patients with non-Hodgkin's lymphoma undergoing chemotherapy: Initial results from an integrated analysis – the Neulasta versus Current Neutropenia Management Practice Project. *J Supp Oncol* 2007; 5:40-41.